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1. INTRODUCTION 
Diabetes mellitus (DM) and especially diabetic neuropathy (DNP) as complication of the un-
derlying disease lead to a major morbidity and mortality resulting in a huge economic burden 
for the society (54). Diabetic neuropathy is the most common form of neuropathy in the de-
veloped countries of the world, accounts for more admission to hospital than all other dia-
betic complications combined and is responsible for 50-75% of non-traumatic amputations 
(54).  
Distal symmetric sensimotor polyneuropathy is the most common from of peripheral neu-
ropathy and is the leading cause of lower limb amputation (18). Diabetic neuropathy can re-
sult in painful neuropathy, disabling foot ulcers, and death from autonomic neuropathy. (20). 
Diabetic neuropathy is a set of clinical syndromes that affect distinct regions of the nervous 
system, singly or combined. The progress of the disease can be silent and go undetected, or 
be present with clinical symptoms and signs that although non-specific and insidious with 
slow progression also mimic those seen in many other diseases (54). Diabetic neuropathy is 
diagnosed by exclusion meaning, that other potential causes of neuropathy should be ex-
cluded (54).  
Patients suffering from diabetic neuropathy can be present with altered sensation, pain, 
weakness, or autonomic symptoms. The clinical picture can vary widely and may resemble 
myelopathy, radiculopathy, muscle disease, or even hyperventilation. As a result of these 
findings identifying a neuropathy in patients with coexistent problems can be therefore diffi-
cult (20). The evaluation and identification of possible causes for neuropathy was improved 
by the so-called neuropathy symptom profile, which is a questionnaire developed by Dyck et 
coworkers (14). 
For the diagnosis of diabetic neuropathy the tools used differ depending on the aim: from 
simple clinical tests to screen for diabetic neuropathy to clinical-neurophysiological methods 
necessary to exclude other diagnoses, stage severity and monitor the course of diabetic neu-
ropathy, to novel investigative techniques, which are highly promising, but their usefulness in 
the clinical setting remains limited at this time (31). 
For the neurologist in usual clinical practice the diagnosis of diabetic neuropathy consists of 
the anamnesis of the patient, inspection (e.g. ulcera cruris, cutis), clinical tests (investigation 
of reflexes, sensation, muscle strength) and neurophysiological tests. Diabetic patients sus-
picious of having a diabetic neuropathy due to symptoms providing hints (e.g. impaired sen-
sation, vibration, etc.) are then usually tested with various neurophysiological tests (motoric 
and sensory tests of peripheral nerves, electromyography, tests of the autonomous nervous 
system) to further evaluate their functional status. Combined with the clinical symptoms and 
 
Page 8 
  
the anamnesis of the patient and by excluding other common causes of neuropathy (e.g. al-
cohol misuse, drugs, paraneoplasia, etc.) (20) the patient will be analyzed and diagnosed.  
Due to the fact, that the measurement of motoric nerve function of peripheral nerves is one of 
the most valid methods (51) that can be applied in the electrophysiological evaluation of pe-
ripheral nerves, this study was designed to measure the motoric function of three peripheral 
nerves (N. medianus, N. tibialis, N. peronaeus). Combined with the anamnesis of the patient 
and the results of the neurological examination this neurophysiological test shall help to iden-
tify those patients with diabetes mellitus, who are at an early stage of diabetic neuropathy. 
Those patients should be engaged to have an optimal control of their glucose metabolism 
with low glycosylated hemoglobin levels, which was proved to keep their disease status or 
slow down the progression of their diabetic neuropathy (35, 45, 49). 
2. PATHOGENESIS OF DIABETIC NEUROPATHY 
The pathogenesis of diabetic neuropathy is not completely understood yet despite huge ef-
forts in preclinical and clinical studies (48, 22, 7, 37, 27, 53). This could be related to the fact, 
that the pathogenesis of peripheral diabetic neuropathy is a very complex and heterogene-
ous mechanism with involvement of different factors, which are probably not comprehen-
sively known and fully analyzed (53, 54, 27, 48). 
Simplified said different concepts are involved in the pathogenesis of DNP so as vascular 
factors, neurochemical factors and pathobiochemical factors (27). The vascular concept of 
DNP implies that diabetes-induced endothelial dysfunction with resulting decrease of nerve 
blood flow and endoneural hypoxia has a key role in functional and morphological changes in 
the diabetic nerve. Endothelial changes in the vasa nervorum have been attributed to multi-
ple mechanisms, including increased aldose reductase activity, nonenzymatic glycoxidation, 
activation of protein kinase C, oxidative stress, changes in arachidonic acid and pros-
taglandin metabolism, and others (27). The neurochemical concept of DNP suggests the im-
portance of similar mechanisms in the neural elements of the peripheral nervous system 
(PNS) (i.e. neurons and Schwann cells). Other pathobiochemical mechanisms in the periph-
eral nervous system have also been invoked. These include  
1) metabolic abnormalities such as downregulation of the Na+/K+-ATPase activity, 
“pseudohypoxia” (i.e. increase in free cytosolic NADH/NAD+ ratio attributed to in-
creased conversion of sorbitol to fructose by sorbitol dehydrogenase),  
2) changes in fatty acid and phospholipids metabolism,  
3) impaired neurotropic support; and  
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4) dorsal root ganglion and Schwann cell mitochondrial dysfunction and premature 
apoptosis. 
The vascular concept of DNP was also supported by results of pathological tests carried out 
in autopsy cases in diabetic patients, which revealed focal fascicular lesions likely due to 
diabetic microangiopathy (22). 
The structural changes within the peripheral nervous system in patients suffering from DNP 
can be classified as  
1) nodal structural changes leading to axo-glial dysfunction and paranodal demyelina-
tion and  
2) axonal structural changes leading to axonal atrophy and fiber loss (37).  
The functional changes related to the former mentioned structural changes are for  
1) a reduction of the nerve conduction velocity (NCV) and for  
2) a reduction of the amplitude of the compound muscle action potential.  
The predominant pathological factor in this context seems to be rather the axonal atrophy as 
main structural abnormality of DNP, as demonstrated in various studies involving both hu-
mans and experimental animals (37). 
3. CLASSIFICATION OF DIABETIC NEUROPATHIES 
The natural course of DNP separates them into two very distinctive entities, namely those 
which progresses gradually with increasing duration of diabetes and those which remit usu-
ally completely. Sensory and autonomic neuropathies usually generally progress, whereas 
mononeuropathies, radiculopathies and acute painful neuropathies, although symptoms are 
severe, tend to be short-lived and often recover (54). Acute painful diabetic sensory neuropa-
thies is therefore a separate entity with a favorable prognosis (47) and will be not further ad-
dressed in this study. 
The progression of DNP is related to the glycemic control in both type I and type II diabetes 
(54). It seems that the most rapid deterioration of nerve function occurs soon after the onset 
of type I diabetes and within 2-3 years there is a slowing of the progress with a shallower 
slope to the curve of dysfunction. In contrast in type II diabetes slowing of nerve conduction 
velocities can be one of the earliest neuropathic abnormalities and often is present even at 
diagnosis (57). After diagnosis, slowing of nerve conduction velocity generally progresses at 
a steady state of approximately 1 m/s per year and the level of impairment is positively corre-
lated with the duration of diabetes. Although most studies have documented that sympto-
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matic patients are more likely to have slower nerve conduction velocities than patients with-
out symptoms, these do not relate to the severity of symptoms.  
In a long-term follow-up study of type II diabetes patients (29) the percentage of patients with 
electrophysiological abnormalities in the lower limb increase from 8% at baseline to 42% af-
ter 10 years: a decrease in sensory and motor potential amplitudes, indicating axonal de-
struction was more pronounced than slowing of the nerve conduction velocities. 
The form of neuropathy found in patients with impaired glucose tolerance (IGT) at early stage 
of diabetes mellitus is predominantly a small-fiber neuropathy, compared to patients with 
diabetes mellitus, who had a more involvement of large nerve fibers (42). 
3.1 Clinical presentation 
The spectrum of clinical neuropathic syndromes described in patients with diabetes includes 
dysfunction of almost every segment of the somatic peripheral and autonomic nervous sys-
tem (54). Each syndrome can be distinguished by its pathophysiological, therapeutic and 
prognostic features. Usually the clinical syndromes be can differentiated into the following 
items: 
• Focal neuropathies 
• Diffuse neuropathies 
o Proximal motor neuropathies (diabetic amyotrophy) 
o Distal symmetric polyneuropathy 
o Small-fiber neuropathy 
o Large-fiber neuropathies 
• Autonomic neuropathies 
3.1.1 Focal neuropathies 
Monoreuropathies are rare in comparison with distal symmetric neuropathies. They usually 
occur primarily in older populations, their onset is often rapid, associated with pain and their 
course is self-limiting, resolving within 6-8 weeks. One example of this clinical entity would be 
the carpal tunnel syndrome, which occurs twice as frequently in people with diabetes com-
pared with normal healthy population and its increased prevalence in diabetes can be related 
to repeated undetected trauma, metabolic changes, or accumulation of fluid or edema with 
the confined space of the carpal tunnel (55).  
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3.1.2 Diffuse neuropathies 
Proximal motor neuropathies (diabetic amyotrophy) has been for many years considered as 
a variant of diabetic neuropathy. It can be clinically identified based on recognition of these 
common features (54): 
1) primarily affects the elderly,  
2) gradual or abrupt onset,  
3) begins with pain in the tighs and hips or buttocks  
4) followed by weakness of the proximal muscles of the lower limbs with the inability to 
rise from the sitting position,  
5) begins unilaterally and spreads bilaterally,  
6) coexists with distal symmetric polyneuropathy and  
7) spontaneous muscle fasciculation, or provoked by percussion.  
The condition is now recognized as being secondary to a variety of causes unrelated to dia-
betes but which have a greater frequency in patients with diabetes than the general popula-
tion. It includes patients with chronic inflammatory demyelinating polyneuropathy (CIPD), 
monoclonal gammopathy, circulating GM1-antibodies and antibodies to neuronal cells and 
inflammatory vasculitis (40). It was formerly thought to resolve spontaneously in 1.5 to 2 
years but now, if found to be immune-mediated, can resolve within days with immunotherapy 
(54).  
Distal symmetric polyneuropathy (DSP) is the most common and widely recognized form of 
diabetic neuropathy. The onset is usually creeping but occasionally rapid, following stress or 
initiation of therapy for diabetes. It can be either sensory or motor and involve small fibers, 
large fibers or both (54). There is now evidence that distal symmetric polyneuropathy can be 
accompanied by loss of cutaneous nerve fibers that stain positive for the neuronal antigen 
PGP9.5 as well as impaired neurovascular blood flow (39). There are however a variety of 
ways in which small fiber neuropathies can be present.  
Small fiber neuropathy can be differentiated between acute and chronic painful form. For 
acute painful neuropathy some patients develop a predominantly small-fiber neuropathy, 
which is manifested by pain and paresthesia early in the course of diabetes. It can be asso-
ciated with the onset of insulin therapy and has been termed “insulin neuritis” (43). By defini-
tion it has been there for less than 6 months. Symptoms are often exacerbated at night and 
are manifested in the feet more than the hands. Spontaneous episodes of pain can be se-
verely disabling. The pain varies in intensity and character. Chronic painful neuropathy per-
sist by definition longer than 6 months and becomes disabling. This condition can result in 
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tolerance to narcotics and analgetics and finally to addiction. It is extremely resistant to all 
forms of intervention, and more frustrating for both patient and physician.  
Large-fiber neuropathies can involve sensory or motor nerves or both. These tend to be neu-
ropathies of signs rather than symptoms. Large fibers subserve motor function, vibration per-
ception, position sense and cold thermal function. Unlike the small fibers these are myeli-
nated, rapidly conducting fibers that begin in the toes and have their first synapse in the me-
dulla oblongata. They tend to be affected first because of their length and tendency in diabe-
tes for nerves to “die back”. Because they are myelinated, they are the fibers represented in 
the electroneurograph and subclinical abnormalities in nerve function are readily detected. 
The symptoms can be minimal; sensation of walking on cotton, floors feeling “strange”, in-
ability to turn the pages of a book or inability to discriminate among coins.  
Most patients with DSP have, however, a “mixed” variety of neuropathy with both large and 
small fiber damage. In the case of distal symmetric polyneuropathy, a “glove and stocking” 
distribution of sensory loss is almost universal (55). Early in the course of the neuropathic 
process, multifocal sensory loss also might be found. In some patients, severe distal muscle 
weakness can accompany the sensory loss resulting in an inability to stand on the toes or 
heels. Some grading systems use this as a definition of severity.  
3.1.3 Autonomic neuropathies 
Diabetic autonomic neuropathy can involve any system in the body. Involvement of the 
autonomous system can occur as early as the first year after diagnosis and major manifesta-
tions are cardiovascular, gastrointestinal, and genitourinary system dysfunction (55). Re-
duced exercise tolerance, edema, paradoxic supine or nocturnal hypertension and intoler-
ance to heat due to defective thermoregulation are a consequence of autonomic neuropathy. 
Silent myocardial infarction, respiratory failure, amputations and sudden deaths are hazards 
for the diabetic patients with cardiac autonomic neuropathy (50). Therefore, it is vitally impor-
tant to make this diagnosis early so that appropriate intervention can be instituted.  
4. DIAGNOSIS OF DIABETIC NEUROPATHIES 
The diagnosis of diabetic neuropathy in clinical practice requires the neurological history and 
physical examination in combination with neurophysiological testing as a criterion standard 
for diagnosis and measurement of severity (31).  
The assessment of neuropathy can be carried out using different tools: one example would 
be the Michigan Neuropathy Screening Instrument, which is an eight-point assessment that 
relies on clinical examination of the feet, the presence or absence of foot ulcerations, the as-
sessment of vibratory sensation in the great toes, and grading of ankle reflexes (38).  
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A more sophisticated and detailed tool would be the neurological symptom score and neu-
ropathy impairment score by Dyck et al (13), which was also used in the Diabetes Control 
and Complication Trial (DCCT) (44). These classifications are however time-consuming and 
therefore inconvenient in daily practice (41).  
The 1988 San Antonio conference on diabetic neuropathy and the 1992 conference of the 
American Academy of Neurology (2, 3) recommended that at least one variable from each of 
the following five categories are measured to classify diabetic neuropathy: symptom profiles, 
neurologic examination, quantitative sensory test (QST), nerve conduction study and quanti-
tative autonomic function testing (QAFT) (54). The least reliable measure is the neurologic 
symptom score. The quantitative sensory test and quantitative autonomic function test are 
objective indices of neurologic functional status. Combined, these tests cover vibratory, pro-
prioceptive, tactile, pain, thermal and autonomic function (54). Nevertheless these tests are 
also quite time-consuming and therefore for daily practice maybe not useful.  
The validity respectively reproducibility of different diagnostic measures in diabetic patients 
was evaluated by Dyck et coworkers (15), the results showed that the neurologic disability 
score (NDS), vibratory and cooling thresholds, compound muscle action potential, sensory 
nerve action potentials, and motor nerve conduction velocities achieved the most reliable re-
sults.  
Perkins (31) stated in his review, that screening for diabetic neuropathy is justified as it offers 
the patient with diabetes a crucial opportunity to actively alter the course of suboptimal gly-
cemic control prior to significant morbidity associated with the natural history of neuropathy. 
For screening purposes three fundamental issues need to be addressed (31): 
1) Specificity, 
2) confirmatory diagnosis and 
3) appropriateness of screening. 
The first issue specificity need be addressed, since distal symmetrical sensimotor deficits 
may arise from such conditions as uremic, toxic, alcoholic, familial, paraneoplastic, and/or 
nutritional neuropathy (17). The second issue is still in discussion, the criterion standard to 
diagnose diabetic neuropathy (DNP) is not finalized yet. The most objective test in the 
evaluation of DNP are the physical examination, quantitative sensory testing and nerve con-
duction studies (NCS). It is generally agreed, that at least two objective tests are required for 
a diagnosis for research purposes (6). Nerve conduction studies are the least subjective of 
these tests since they are independent of patient psychophysical interpretation and they pro-
vide reliable, quantitative measures of nerve function. The lack of sensitivity for isolated small 
fiber neuropathy is however a criticism of the use of nerve conduction studies alone, al-
though the clinical importance of this form of neuropathy is likely insignificant in the context of 
DNP, in which the progressive loss of all nerve fibers is observed.(16). The third issue ad-
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dresses the common prerequisites to justify the necessity for the screening for certain sub-
jects so as the relevance of the disease, the consequences of the natural course of the dis-
ease, the possibility to positively influence the course of the disease and the availability of a 
simple and accurate test suitable for diabetes or primary care.  
Another proposal for the screening of large numbers of diabetic patients from Simmons et al 
(38) proposes the use of inexpensive, rapid methods e.g. the use of monofilaments to meas-
ure touch sensitivity and the use of tactile circumference discrimination.  
Meijer et coworkers (25) tested the possibility to differentiate between three patient groups 
(group 1: diabetic patients with diabetic foot ulcers; group 2: 24 diabetic patients without 
clinical neuropathy; and group 3: 21 control subjects without diabetes) with the diabetic neu-
ropathy score (DNS), the diabetic neuropathy examination score (DNE), and their relation-
ship with cardiovascular autonomic function testing (CAFT) and electrodiagnostic studies 
(EDS). Both scores were able to discriminate between group 1 and group 2 significantly 
(p<0.001). The diabetic neuropathy examination score discriminated also between group 2 
and group 3 (p<0.05). Spearman’s correlation coefficients between both scores and cardio-
vascular autonomic function testing and electrodiagnostic studies were high.  
Perkins et coworkers (32) investigated the diagnostic value of four different simple sensory 
tests (the 10-g Semmes-Weinstein monofilament examination [SWME], superficial pain sen-
sation, vibration testing by the on-off method, and vibration testing by the timed method) as 
screening tests for peripheral neuropathy in the diabetes clinic. Therefore these tests were 
carried out in 478 subjects with independent blinded evaluations compared against the crite-
rion standard of nerve conduction studies. The results gained were convincing for superficial 
pain sensation testing, Semmes-Weinstein monofilament examination, or vibration testing by 
the on-off method.  
The value of nerve fiber conduction velocity distributions as additional diagnostic criteria for 
diabetic neuropathy was evaluated by Cummins et coworkers (10). He found a shift of to-
wards slower conduction velocities in diabetic patients with minimal or no clinical neuropathy, 
but these findings were obtained in the elbow-to-axilla segment of the N. medianus. 
The conduction slowing observed in diabetic patients was also evaluated by Herrmann et 
coworker (19) in comparison to patients suffering from amyotrophic lateral sclerosis (ALS), 
where a form of neuropathy with a loss of large axons is observed. The findings suggested 
that the nerve conduction velocity slowing was due to an amplitude-dependent mechanism in 
both diabetic patients and ALS patients in the upper and lower extremities, consistent with a 
loss of large myelinated fibers. In addition in diabetic patients also a significant amplitude-
independent slowing in intermedia but not in distal nerve segments was found, supporting 
that an additional demyelinative component could be observed.  
The influence of aging to changes of the compound muscle action potential (CMAP) in pa-
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tients without clinical neuropathy was investigated by Kurokawa (24). He found, that the am-
plitude of the compound muscle action potential was lower in older patients, however the 
compound muscle action potential ratio (proximal CMAP/distal CMAP) did not change with 
age. The compound muscle action potential duration or interval and the corresponding ratio 
was not different in groups of patients with different age, but the compound muscle action po-
tential area was smaller in older patients, the area ratio nevertheless remained almost con-
stant. 
 
To summarize: Nerve conduction studies remain the most reliable, accurate, and sensitive 
measure of peripheral nerve function (1). These have long been a gold standard for the di-
agnosis of all neuropathies (11) and are, most simply considered, an extension of the clinical 
neurological examination. The nerve conduction study findings correlate with the clinical 
endpoints (32), and the nerve potential amplitudes reflect the degree of nerve fiber loss (34). 
Standardized methods improve the reliability of testing such that nerve conduction studies 
have the lowest degree of variance of all tests in diabetic neuropathy (51). The prevalence of 
abnormal nerve conduction velocities increases with duration of diabetes (1), and disease 
severity correlates with glycemic control (21). Only small changes in parameters are ob-
served In intervals as long as 5 years, particularly in the setting of acceptable glycemic con-
trol (45). The small changes in conduction velocity are readily demonstrable, but amplitude 
changes are more difficult to show due to higher variability of this measures (9). Two poten-
tial disadvantages must be considered for the use of nerve conduction studies: the limit of 
availability of nerve conduction testing for routine diagnostic evaluation and the insensitivity 
for the identification of small fiber neuropathy (16).  
All these findings are interesting for further diagnostic measures for early detection of dia-
betic neuropathy in patients suspicious of having diabetic neuropathy and need to be re-
evaluated in this patient population in a comparison to a “normal” population without diabetes 
and clinical signs for any form of neuropathy. 
5. THERAPY OF DIABETIC NEUROPATHY 
This section describes the treatment of diabetic neuropathy without considering the treatment 
of symptomatic diabetic neuropathy. 
Despite huge efforts for clinical research in treatment of DNP the value of intensive glycemic 
control remains as the most important issue in this context (30).  
The Diabetes Control and Complications Trial showed that maintenance of an intensive ther-
apy intervention, resulting in a mean hemoglobin A1 concentration of 7.2%, as compared 
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with conventional therapy, resulting in a mean of 9.1%, reduced the risk of neuropathy by 
60% (95% CI: 38% to 74%) (44). A weakness of this and other studies of the effect of glyce-
mic control is that they used surrogate measures for the improvement (or slowing of progres-
sion) of neurologic function (28). Most used sensory or motor nerve conduction studies and 
some used vibration perception thresholds. Whether such measures correlate reliably with 
neuropathy symptom scores, neurologic examination, quality-of-life, neuropathic complica-
tions (foot ulcers and amputation), and mortality remains controversial. Nevertheless: as a 
result of these studies patients should be treated with a goal of glycated hemoglobin less 
than 7% (30).  
Measures other than improved glycemic control and symptomatic control of painful symp-
toms can improve the prognosis for patients with DNP. Beside glycemic control other ap-
proaches to treat DNP so as aldose reductase inhibitors (ARI), which aims to protect nerves 
from the effects of overactivity of the polyol pathway caused by chronic hyperglycemia (8). 
Several substances were clinically tested with negative results for various reasons (negative 
clinical results, side effects, poor study data quality).  
Neurotropins such as nerve growth factors used to stimulate the growth of nerves, which 
demonstrated encouraging results in preclinical and early clinical studies (4), failed also in 
phase III clinical trials, due to poor efficacy results or side effects observed (8).  
Anti-oxidant therapy  (e.g. alpha-lipoic acid) which shall improve the blood flow is still in clini-
cal investigations and need to be reconsidered.  
Summarizing it can be stated, that beside optimal glycemic control no other convincing ther-
apy option consists for the treatment of DNP. Beside this specific approaches more common 
measures as preventing of known toxic substances (e.g. alcohol, prevention of vitamin defi-
ciencies, certain drugs), reduction of known risk factors (e.g. hypertension, hypercholes-
terolemia, smoking) and prevention of complications (podiatry, hygiene, appropriate stock-
ings and shoes, weight reduction) need to be considered also (26).  
6. AIM OF THE STUDY 
Due to the high risk for foot ulceration in patients with distal symmetric polyneuropathy, which 
may lead to lower limb amputation and high financial burden for the society it is mandatory to 
optimize the early diagnosis of these disease (46). The early identification of the neuropathic 
process in diabetic patients is justified as it offers the patient a crucial opportunity to actively 
alter the course of suboptimal glycemic control prior to significant morbidity associated with 
the natural course of neuropathy in these patients (31). It is likely that effective intervention 
will be possible only during the subclinical or early phase of dysfunction in diabetic patients 
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(5).  
The impact and diagnostic value of determination of motor nerve conduction velocities 
(mNCV) as early diagnostic tool for diabetic neuropathy is well accepted. (41, 23). This non-
invasive and easy-to-generate method is frequently used in neurophysiological examinations. 
In general the assessment of this diagnostic tool in terms of reproducibility and validity as a 
prerequisite for comparing analyzes demonstrates, that this tool used professional is able to 
be utilized for diagnosis and staging of diabetic neuropathy (33, 51). A comparative study in-
vestigating whether it is sufficient to test only one side of peripheral nerves for nerve conduc-
tion velocity analyses revealed, that in patients with diabetic neuropathy interside symmetry 
can be considered (33). Therefore it is acceptable for studies in this field to rely on data col-
lected in patients from one side. Parameters usually applied for the testing of peripheral mo-
tor nerves are the determination of the maximum nerve conduction velocity, amplitude of the 
compound muscle action potential (CMAP), latency and F-wave latency (12). It can be as-
sumed, that these parameters could become pathological not in the early course of disease 
but in later stages.  
Therefore the aim of this study was to determine, whether there are additional ways in ana-
lyzing the neurophysiological status of the peripheral nerve system in the case suspected 
diabetic neuropathy in an early stage of disease. The determination of the maximum motor 
nerve conduction identifies only demyelination of the fastest nerve fibers, which represent 
only a minority of the profile of the complete nerve (41). Up to now it is still in discussion, 
whether DNP is based on a loss of nerve fibers or a process of demyelinisation or on both, 
and if both processes are involved, which of both are involved in the beginning of the process 
(52, 23).  
Therefore a study was carried out comparing two groups of patients to test additional pa-
rameters for the evaluation of peripheral motor nerve function beside the parameters already 
mentioned above. In the group 1 inpatients of the Neurologische Universitätsklinik Marburg 
were included, who  
1) had no diabetes mellitus,  
2) had no clinical signs of any neuropathy,  
3) were not suspected to have any alcohol abuse,  
4) gave their informed consent for the tests carried out.  
 
In group 2 patients  
1) having impaired glucose tolerance or manifest diabetes mellitus,  
2) clinical signs of distal symmetric DNP and  
3) with informed consent  
were included and investigated. The parameters tested additionally beside the parameters 
 
Page 18 
  
already mentioned are described and defined in the section 8.2 Neurophysiological investiga-
tion (8.2). Summarized following characteristics of the compound muscle action potential 
shall be analyzed: 
1) Since the usual nerve conduction velocity determination analyzes only the fastest 
nerve fibers, additionally the nerve conduction velocities of the other characteristic 
CMAP markers shall be analyzed in order to further characterize not only the fastest 
nerve fibers, but also slower-conducting nerve fibers. 
2) The changes of the characteristics of the CMAP (amplitudes, intervals, areas) from 
distal to proximal stimulation due to dispersion of the CMAP (24, 56) will be evaluated 
by calculation of the quotient of the corresponding proximal and distal values (e.g. 
proximal maximum amplitude divided by distal maximum amplitude). 
3) The area under the curves (distal and proximal) of the CMAP provide further informa-
tion about the quantity of nerve fibers tested and shall be therefore analyzed. 
4) Intervals of the CMAP (distal and proximal) further characterize the function of pe-
ripheral nerves and shall be therefore analyzed. 
5) In addition to the maximum amplitude of the compound muscle action potential also 
parts of the amplitude (positive/negative amplitude) shall be analyzed. 
 
The Zero-Hypothesis for this study will be therefore defined as following: 
 
For the support of the diagnosis of diabetic neuropathy other parameters (as de-
scribed above) than maximum nerve conduction velocity and compound muscle ac-
tion potential amplitude do not differentiate with statistical significant results between 
healthy persons and patients suspicious of having diabetic neuropathy. 
7. STATISTICAL ISSUES 
All relevant data collected for the neurophysiological investigations were transferred into a 
data table (Excel 2000) and analyzed by a statistician program (SPSS 11.5). A non-
parametric test (Mann-Whitney test) was applied to compare the parameters for both patient 
groups. In addition descriptive statistical parameters (mean, standard deviation [SD], median, 
minimum, maximum, percentile 25/50/75) were provided for both patient groups. Relevant 
results of the analysis were transferred into boxplots.  
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8. PATIENTS AND METHODS 
8.1 Patients 
All patients included in this study were inpatients of the Neurologische Universitätsklinik Mar-
burg. In order to comply with ethical standards to study was evaluated and accepted by the 
ethical committee of the Universitätsklinik Marburg before initiation. All patients gave their in-
formed consent prior recruitment. The further details of the ethical background of the study 
are summarized in section Ethical issues (13.2). 
All patients who have participated in this study were examined after following scheme: 
1) Common anamnesis 
2) Anamnesis for diabetes mellitus  
3) Anamnesis for neuropathic symptoms (NS) 
4) Neurological examination for neuropathic deficits (ND) 
For group 1 following items were checked before recruitment: 
1) Patients with diabetes mellitus were excluded 
2) Patients with clinical symptoms for any neuropathy were excluded 
3) Patients with suspicion of having any alcohol abuse were excluded 
4) Patients have to give their written informed consent 
In group 1 32 female and 35 male patients were included. The average age (±SD) was 49 
years( ±28 years).  
For patients of group 2 following items were checked prior recruitment: 
1) Patients need to have at least impaired glucose tolerance test results or manifest 
diabetes mellitus 
2) Patients with clinical signs of neuropathy 
3) Patients with written informed consent. 
In group 2 9 female and 12 male patients were included, the average age (±SD) was 68 
years (±17 years). The average time elapsed (±SD) since diagnosis of diabetes mellitus or 
impaired glucose tolerance (IGT) was 12.1 years ( ±7.3 ys). In 2 of 21 cases type I diabetes 
mellitus was diagnosed, in 7 cases type II diabetes mellitus, in 12 cases unknown. 6 Patients 
suffered from insulin-dependent diabetes mellitus (IDDM), 6 from non-insulin-dependent dia-
betes mellitus (NIDDM), 9 cases unknown. The results of nerves investigated were available 
in 18, 19 respectively 15 cases (N. medianus, N. tibialis, N. peronaeus). In 19 out of 21 pa-
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tients symptoms of diminished or altered sensation could be observed, in 2 patients the re-
duction or absence of reflexes was the only symptom of DNP.  
The difference with regard to the average age between group 1 and group 2 could have 
some impact on the results, since it is known that age of patients could influence the nerve 
conduction (36) or CMAP amplitude (24). This issue will be considered later in the section 
Discussion (10). 
The definition of the gender of the patients is as following: 1 means female, 2 means male. 
The detailed information about patients in group 2 is provided in the following table 1:
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  Table 1 
D
etails of patients in group 2 
Patient 
N
o. 
Initials 
 
Sex 
A
ge at 
exam
i-
nation 
D
M
 
type
D
iabetes 
m
ellitus 
dura-
tion (ys)
N
ID
D
M
 
or ID
D
M
Sym
ptom
s of diabetic neuropathic sym
p-
tom
s/deficits, diabetes m
ellitus inform
a-
tion, antidiabetic m
edication (if know
n) 
N
. m
e-
dianus 
N
. tibi-
alis 
N
. pero-
naeus 
1 
H
K 
2 
74 
n.k. 
n.k. 
n.k. 
Pallanesthesia legs, distal pronounced hypes-
thesia and hypalgesia, Achilles tendon reflex  
-/- 
X
 
X
 
X
 
2 
AE 
1 
20 
I 
23 
ID
D
M
 
H
ypesthesia left upper leg lateral and ventral 
X
 
X
 
X
 
3 
LB 
2 
30 
I 
20 
ID
D
M
 
Pallhypesthesia, Achilles tendon reflex reduc-
tion on both sides 
X
 
X
 
X
 
4 
BH
 
2 
66 
II 
5 
N
ID
D
M
 
Pallhypesthesia 4/8 at both low
er legs, Achil-
les tendon reflex -/-, Euglucon 2-0-1 
X
 
X
 
X
 
5 
JW
 
2 
64 
II 
n.k. 
n.k. 
D
istal sym
m
etric hypesthesia in both low
er 
legs (m
iddle low
er legs), pallhypesthesia 5/8 
X
 
X
 
X
 
6 
H
H
 
1 
82 
II 
n.k. 
n.k. 
Achilles tendon reflex -/-, paresthesia and 
hypesthesia in both low
er legs  
X
 
X
 
- 
7 
EH
 
2 
67 
II 
10 
N
ID
D
M
 
Pallhypesthesia 4/8, stocking-like hypesthesia 
both low
er legs, G
lyko-H
b 9,5 m
g/dl, Euglu-
con 1-1-0 
X
 
X
 
- 
8 
JK 
1 
86 
II 
10 
N
ID
D
M
 
Paresthesia both feet, pallhypesthesia 5/8, 
Achilles tendon reflex reduction on both 
sides, dietetic treatm
ent of diabetes m
ellitus 
X
 
X
 
X
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  Patient 
N
o. 
Initials 
 
Sex 
A
ge at 
exam
i-
nation 
D
M
 
type
D
iabetes 
m
ellitus 
d<<ura-
tion (ys)
N
ID
D
M
 
or ID
D
M
Sym
ptom
s of diabetic neuropathic sym
p-
tom
s/deficits, diabetes m
ellitus inform
a-
tion, antidiabetic m
edication (if know
n) 
N
. m
e-
dianus 
N
. tibi-
alis 
N
. pero-
naeus 
9 
W
S 
2 
65 
n.k. 
30 
n.k. 
Pallanesthesia both low
er legs, hypalgesia on 
both arm
s and legs 
 
X
 
X
 
10 
A
M
 
2 
69 
II 
2 
N
ID
D
M
 
D
istal sym
m
etric pallhypesthesia. 4/8, Euglu-
con 2-0-0 
X
 
X
 
X
 
11 
H
H
 
1 
78 
n.k. 
n.k. 
ID
D
M
 
Pallhypesthesia on both legs 6/8, Achilles 
tendon reflex -/-, D
epot H
 24-0-12 
X
 
- 
- 
12 
G
M
 
1 
82 
n.k. 
n.k. 
n.k. 
Pallhypesthesia 5/8 at both low
er legs, distal 
sym
m
etric hypesthesia in both low
er legs, 
pathological oral glucose tolerance test 
X
 
X
 
X
 
13 
G
P 
2 
73 
n.k. 
n.k. 
n.k. 
Pallhypesthesia low
er legs, Achilles tendon 
reflex -/-, diabetic m
etabolism
 
X
 
X
 
X
 
14 
AB 
1 
68 
IIb 
n.k. 
N
ID
D
M
 
Pallhypesthesia both feet, Achilles tendon re-
flex reduction on both sides, posture sense 
dysfunction both feet, Euglucon 2-0-0 
X
 
X
 
- 
15 
EW
 
1 
80 
n.k. 
>10 ys. 
N
ID
D
M
 
Pallhypesthesia distal low
er extrem
ities, pa-
tella tendon reflexes and Achilles tendon re-
flexes -/-, Euglucon 1-0-0 
- 
X
 
X
 
16 
R
L 
2 
54 
n.k. 
9 
ID
D
M
 
M
ild pallhypesthesia on both low
er legs, 
Achilles tendon reflex reduction on both sides
- 
X
 
X
 
 
Page 23 
  Patient 
N
o. 
Initials 
 
Sex 
A
ge at 
exam
i-
nation 
D
M
 
type
D
iabetes 
m
ellitus 
dura-
tion (ys)
N
ID
D
M
 
or ID
D
M
Sym
ptom
s of diabetic neuropathic sym
p-
tom
s/deficits, diabetes m
ellitus inform
a-
tion, antidiabetic m
edication (if know
n) 
N
. m
e-
dianus 
N
. tibi-
alis 
N
. pero-
naeus 
17 
G
G
 
2 
62 
n.k. 
approx. 8 
ys. 
N
ID
D
M
 
Paresthesia feet, posture sense dysfunction 
both feet, Achilles tendon reflexes -/- 
X
 
X
 
X
 
18 
G
S 
2 
65 
n.k. 
approx. 
11 ys. 
ID
D
M
 
Pallhypesthesia, patella tendon reflexes -/-, 
Achilles tendon reflexes -/-, D
epot H
 36-0-10 
X
 
- 
- 
19 
KG
 
2 
71 
n.k. 
n.k. 
n.k. 
Pallhypesthesia low
er extrem
ities, patella 
tendon reflex reduction on both sides, Achil-
les tendon reflexes -/- 
X
 
X
 
- 
20 
KK 
1 
73 
n.k. 
9 
n.k. 
Achilles tendon reflexes -/- 
X
 
X
 
X
 
21 
JS 
2 
87 
n.k. 
14 
ID
D
M
 
Achilles tendon reflexes reduced on both 
sides, pallhypesthesia, D
epot H
 30-0-16, Eu-
glucon 1-0-1 
X
 
X
 
X
 
Sum
 per nerve (n=) 
18 
19 
15 
 (n.k. not know
n; D
M
 diabetes m
ellitus; ID
D
M
 insulin dependent diabetes m
ellitus; N
ID
D
M
 non-insulin dependent diabetes m
ellitus; ys years; no. 
num
ber; sex: 1 = fem
ale, 2 = m
ale)
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8.2 Neurophysiological examinations 
The measurements were carried out with an usual device for neurophysiological examina-
tions (Neuropack 4 by Nihon Kohden/Japan). 
Following parameters of the device were kept up during all measurements: 
• Sensitivity of the amplifier 5 mV 
• Upper filter frequency 3 kHz 
• Lower filter frequency 20 kHz  
• Delay time 0 ms 
• Stimulation  frequency 1 Hz 
• Stimulation duration 0.2 ms 
• Stimulation type: single 
Following parameters were changed during the measurements: 
• Analysis time (X axis) from 20-50 ms depending on the length of the CMAP. 
• Analysis amplitude (Y axis) 1-5 mV/DIV depending on the amplitude of the CMAP. 
• Stimulation intensity: beginning with 20 mA increased in steps of 5 mA until no 
change of the CMAP could be observed (maximum 99mA). 
The parameters were determined on the Nn. medianus, tibialis and peronaeus on one side of 
the patients. Before carrying out the measurements the temperature of the skin was deter-
mined by a sensor and eventually corrected with the help of a red light lamp (if surface tem-
perature was < 32 oC). During testing the patients were lying on a stretcher. 
The skin of the patients was cleaned with an alcoholic pad and the surface electrodes 
(Ag/AgCl 13mmx7mmx1,5mm) were fixed after application of electrode gel. 
The different electrode was fixed above the muscle belly, the indifferent electrode was fixed 
above the tendon of the muscle (see figure 1). To get an optimal compound muscle action 
potential the position of the different electrode was corrected if necessary. The grounding 
electrode was moistened and connected to the wrist (N. medianus) or the ankle (N. tibialis, 
N. peronaeus). Following nerves were tested: 
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Table 2 Tested nerves 
Nerve Muscle for recording Stimulation distal Stimulation proximal
N. medianus M. abductor pollicis bre-
vis 
Radial wrist Elbow near the bra-
chial artery 
N. tibialis M. extensor digitorum 
communis 
Upper part behind 
the medial malleolus 
Middle part of the 
popliteal space 
N. peronaeus M. extensor digitorum 
brevis 
Ventral side of the 
distal lower leg 
Near the capitulum 
fibulae 
 
The stimulation sides were marked and the corresponding distance was measured in mm by 
a tape-measure. All neurophysiological examinations were printed and stored via hard disk.  
The examinations were analyzed for following variables: 
• Nerve conduction velocities (NCV1-4) of the compound muscle action potential 
(CMAP) 
• Intervals of the CMAP (distal and proximal) 
• Amplitudes of the CMAP (distal and proximal) 
• Areas of the CMAP (distal and proximal) 
• Quotients of the before mentioned variables (each proximal parameter divided by dis-
tal parameter). 
The different stimulation sites are described by addition of a prefix (distal = D / proximal = P) 
to the marker (e.g. PL1). Intervals were shortened as IL, amplitudes as A, areas as AR, and 
quotients as prefix with Q (example QAR = quotient area). 
The parameters evaluated are defined and explained in the following figures 1-8: 
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  Figure 1  
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  Figure 2  
D
efinition of the different m
arkers in the com
pound m
uscle action potential  
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  Figure 3  
D
efinition of the different param
eters of the com
pound m
uscle action potential  
(C
M
A
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  Figure 4  
S
chem
atic picture of the determ
ination of the nerve conduction velocity (N
C
V
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  Figure 5  
S
chem
atic picture of the determ
ination of nerve conduction velocity 1-4  
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C
V
 1-4) 
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  Figure 6  
S
chem
atic picture of the determ
ination of the interval quotients (Q
IL) 
Interval D
IL 13
 
Interval P
IL 13
 
Interval P
IL 14
 
P
IL 13
 
Q
uotient IL 13 ( Q
IL 13
 )  =  ________ 
D
IL 13
 
P
IL 14
 
Q
uotient IL 14 ( Q
IL 14
 ) =  ________ 
D
IL 14
 
Q
uotient IL 13 ( Q
IL 13
 )  =  ________ 
Q
uotient IL 14 ( Q
IL 14
 ) =  ________ 
Interval D
IL 14
 
Q
uotient IL 13 ( Q
IL 13
 )  =  ________ 
Q
uotient IL 14 ( Q
IL 14
 ) =  ________ 
E
xplanation: 
 Q
IL = quotient interval 
 D
IL = distal interval 
 P
IL = proxim
al interval 
 
Page 32 
  Figure 7  
S
chem
atic picture of the determ
ination of the area quotients (Q
A
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  Figure 8  
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9. RESULTS 
In the following sections the results of the testing of the three different nerves (N. medianus, 
N. tibialis, N. peronaeus) are presented. As a rule comparisons were carried out between 
group 1 and group 2, shortened as GR 1 and GR 2. The complete tables with all analyzed 
data (frequencies with descriptive statistics, ranking, results of Mann-Whitney tests, boxplots) 
are summarized in section 13.1 Listing of tables/boxplots (13.1). In this section only the re-
sults of the Mann-Whitney tests for the analyzed parameters are presented together with 
relevant boxplots. The prefixes D and P before the variables characterize them either as dis-
tal or proximal stimulated. The single characteristics of the variables were defined in section 
8.2. Neurophysiological examinations (8.2). Results for asymptomatic significance as shown 
below are qualified to be statistical significant, if the values provided were < 0.05. 
9.1 N. medianus 
9.1.1 Distal and proximal intervals, amplitudes and areas 
The testing of proximal and distal intervals (IL13 and IL14) and distal areas (DAR13 and 
DAR14) showed insignificant results. For distal amplitude DA14 also insignificant results 
were obtained, whereas proximal amplitude PA14 and proximal area PAR13 and PAR14 
showed significant results. Amplitudes (A12, A24) showed both significant results for distal 
and proximal stimulation. The switch from insignificant results to significant results, which can 
be demonstrated here in some cases from distal to proximal stimulation, could be explained 
by the probably stronger influence of dispersion in proximal stimulation due to longer dis-
tance from the stimulation point to the derivation point. The best results in terms of differen-
tiation between group 1 and group 2 can be achieved be focusing on the amplitudes (maxi-
mum amplitude of the CMAP = A24 and amplitude of the first part of the CMAP = A12), 
which can be seen in the boxplots below.  
 
Distal variables 
Test Statisticsa
570,000 595,500 398,000 454,000 390,500 435,500 448,500
2848,000 766,500 569,000 625,000 561,500 606,500 619,500
-,355 -,081 -2,205 -1,603 -2,286 -1,728 -1,586
,723 ,936 ,027 ,109 ,022 ,084 ,113
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
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Proximal variables 
Test Statisticsa
527,000 558,500 351,500 382,500 353,000 386,500 412,500
2805,000 2836,500 522,500 553,500 524,000 557,500 583,500
-,818 -,479 -2,705 -2,372 -2,689 -2,262 -1,979
,413 ,632 ,007 ,018 ,007 ,024 ,048
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
Boxplots for distal positive amplitude 12 (DA12) and proximal  positive amplitude 12 
(PA12) 
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Boxplots for distal maximum amplitude 24 (DA24) and proximal maximum amplitude 
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Boxplots for proximal negative amplitude 14 (PA14) and proximal area 14 (PAR14) 
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Boxplots for proximal area 13 (PAR13) 
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9.1.2 Nerve conduction velocities 
The analysis of the nerve conduction velocities (NCVs) showed for all NCVs highly significant 
results in terms of differentiation between group 1 and group 2. This can also been demon-
strated in the corresponding Boxplots. 
Test Statisticsa
256,500 252,500 197,000 234,000
427,500 423,500 368,000 405,000
-3,728 -3,770 -4,368 -3,970
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
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Boxplots for nerve conduction velocity 1 (NCV1) and 2 (NCV2) 
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Boxplots for nerve conduction velocity 3 (NCV3) and 4 (NCV4) 
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9.1.3 Interval, amplitude and area quotients 
The analysis of the quotient evaluation demonstrated also for all quotients significant differ-
ences between group 1 and group 2, only for the interval quotient QIL13 this level was not 
reached. This result indicates, that also for parameters, which were singular tested not sig-
nificant (either distal or proximal, e.g. interval IL14), that by combination of both entities (dis-
tal and proximal) into one variable the result becomes a significant level. The results are ad-
ditional displayed in the corresponding boxplots. 
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Test Statisticsa
447,500 384,000 359,000 343,000 323,000 321,000 370,000
2725,500 2662,000 530,000 514,000 494,000 492,000 541,000
-1,673 -2,356 -2,625 -2,797 -3,012 -2,976 -2,442
,094 ,018 ,009 ,005 ,003 ,003 ,015
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
Boxplots for interval quotient 14 (QIL14) and positive amplitude quotient 12 (QA12) 
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Boxplots for negative amplitude quotient 14 (QA14) and maximum amplitude quotient 
24 (QA24) 
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Boxplots for area quotient 13 (QAR13) and area quotient 14 (QAR14) 
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9.1.4 Summary 
Summarized for the results of the testing of N. medianus it can be stated, that the results ob-
tained showed a clear evidence, that the best differentiation between group 1 and group 2 
can be obtained, by analyzing the data with regard to the NCVs. Due to a very high level of 
significance in this group (NCV1-4) no differences can be made between these 4 variables in 
terms of preference of a single variable. Nevertheless the impression from the box plot 
evaluation of NCV2 and NCV3 showed interestingly lower variance compared to NCV1 pro-
viding a hint, that they may could be used to better discriminate between group 1 and 2. The 
next variables able to discriminate between the two groups were the amplitudes (maximum 
amplitude and amplitude of the first part of the CMAP=A12) and the quotients derived from 
the amplitude, area and interval variables (exception: IL13). No differentiation can be derived 
from using single interval variables. Summarized these results could be interpreted that way, 
that for the pathophysiology of DNP in the N. medianus a major impact of demyelination fol-
lowed by axonal degeneration could explain the results found in this neurophysiological test-
ing in diabetic and non-diabetic patients. 
9.2 N. tibialis 
9.2.1 Distal and proximal intervals, amplitudes and areas 
The results obtained for N. tibialis in this section revealed non-significant results only for the 
evaluation of distal and proximal intervals (IL13 and IL14). For all other parameters highly 
significant results were obtained for all amplitudes (A12, A14, A24) and areas (AR13, AR14).  
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Distal variables 
Test Statisticsa
556,500 573,000 223,000 188,000 202,500 213,000 215,500
2834,500 2851,000 413,000 378,000 392,500 403,000 405,500
-,833 -,661 -4,305 -4,669 -4,518 -4,367 -4,341
,405 ,509 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
 
Proximal variables 
Test Statisticsa
454,500 483,500 148,500 170,000 164,000 173,000 196,000
2732,500 2761,500 338,500 360,000 354,000 363,000 386,000
-1,895 -1,593 -5,080 -4,856 -4,919 -4,789 -4,547
,058 ,111 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
Boxplots for distal positive amplitude 12 (DA12) and proximal positive amplitude 12 
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Boxplots for distal negative amplitude 14 (DA14) and proximal negative amplitude 14 
(PA14) 
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Boxplots for distal maximum amplitude 24 (DA24) and proximal maximum amplitude 
24 (PA24) 
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Boxplots for distal area 13 (DAR13) and proximal area 13 (PAR13) 
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Boxplots for distal area 14 (DAR14) and proximal area 14 (PAR14) 
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9.2.2 Nerve conduction velocities 
The evaluation of the differences of NCVs revealed for all NCVs highly significant results, no 
differences between single NCVs could be observed. 
Test Statisticsa
133,500 75,000 76,500 99,500
323,500 265,000 266,500 289,500
-5,237 -5,845 -5,829 -5,590
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
 
Boxplots for nerve conduction velocity 1 (NCV1) and 2 (NCV2) 
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Boxplots for nerve conduction velocity 3 (NCV3) and 4 (NCV4) 
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9.2.3 Interval, amplitude and area quotients 
Also the evaluation of quotients resulted in almost all cases in significant differences between 
group 1 and group 2 (QIL13, QIL 14, QA12, QA24, QAR13, QAR14). Only for the quotient of 
the amplitude A14 (QA14) non-significant results were obtained. 
Test Statisticsa
372,000 407,000 213,000 519,500 264,000 351,000 400,000
2650,000 2685,000 403,000 709,500 454,000 541,000 590,000
-2,753 -2,389 -4,408 -1,218 -3,877 -2,911 -2,395
,006 ,017 ,000 ,223 ,000 ,004 ,017
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
Boxplots for interval quotient 13 (QIL13) and interval quotient 14 (QIL14) 
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Boxplots for positive amplitude quotient 12 (QA12) and maximum amplitude quotient 
24 (QA24) 
1967N =
GR
21
Q
A1
2
1,0
,9
,8
,7
,6
,5
,4
,3
1967N =
GR
21
Q
A2
4
1,1
1,0
,9
,8
,7
,6
,5
 
 
Boxplots for area quotient 13 (QAR13) and area quotient 14 (QAR14) 
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9.2.4 Summary 
The evaluation of the results obtained for N. tibialis showed for almost all parameters investi-
gated significant or even highly-significant differences for the comparisons between group 1 
and group 2. Only parameters, which were tested also for N. medianus to be non-significant 
like intervals (IL13 or IL14), showed similar results. In contrast to the results obtained for N. 
medianus the level of significance between NCVs and amplitudes/areas could not be dem-
onstrated here providing hints, that in N. tibialis the degree of DNP could be more advanced 
than in N. medianus. 
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9.3 N. peronaeus 
9.3.1 Distal and proximal intervals, amplitudes and areas 
The evaluation of the results from N. peronaeus showed almost identical results compared to 
N. tibialis. Beside interval variables (IL13, IL14) for all other parameters (both amplitudes and 
areas) highly significant results were obtained.  
Distal variables 
Test Statisticsa
415,500 427,000 123,000 194,000 130,000 104,000 132,500
535,500 547,000 243,000 314,000 250,000 224,000 252,500
-1,044 -,906 -4,552 -3,701 -4,468 -4,754 -4,408
,297 ,365 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
 
Proximal variables 
Test Statisticsa
502,000 483,000 123,500 115,000 114,500 106,000 125,000
622,000 603,000 243,500 235,000 234,500 226,000 245,000
-,006 -,234 -4,546 -4,648 -4,654 -4,730 -4,499
,995 ,815 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
Boxplots for distal positive amplitude 12 (DA12) and proximal positive amplitude 12 
(PA12) 
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Boxplots for distal negative amplitude 14 (DA14) and proximal negative amplitude 14 
(PA14) 
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Boxplots for distal maximum amplitude 24 (DA24) and proximal maximum amplitude 
24 (PA24) 
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Boxplots for distal area 13 (DAR13) and proximal area 13 (PAR13) 
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Boxplots for distal area 14 (DAR14) and proximal area 14 (PAR14) 
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9.3.2 Nerve conduction velocities 
For NCVs of N. peronaeus also for almost all NCVs (beside NCV1) highly significant results 
have been shown, the level of significance had a tendency to improve from NCV1 to NCV3/4. 
Test Statisticsa
276,500 225,000 203,000 206,500
396,500 345,000 323,000 326,500
-2,711 -3,328 -3,592 -3,550
,007 ,001 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
 
Boxplots for nerve conduction velocity 1 (NCV1) and 2 (NCV2) 
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Boxplots for nerve conduction velocity 3 (NCV3) and 4 (NCV4) 
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9.3.3 Interval, amplitude and area quotients 
The results obtained for the quotient variables showed a different picture compared to the re-
sults obtained from N. tibialis. Here for interval quotients (QIL13, QIL14) significant differ-
ences were found, whereas for all other variables for amplitudes (QA12, QA14, QA24) and 
areas (QAR13, QAR14) non-significant results were obtained.  
Test Statisticsa
219,000 256,500 351,500 432,500 345,500 477,500 374,500
2497,000 2534,500 471,500 552,500 465,500 597,500 494,500
-3,400 -2,951 -1,811 -,840 -1,883 -,213 -1,465
,001 ,003 ,070 ,401 ,060 ,832 ,143
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
Boxplots for interval quotient 13 (QIL13) and interval quotient 14 (QIL14) 
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9.3.4 Summary 
The analysis of the results for N. peronaeus showed similar results compared to N. tibialis. 
The results obtained with the highest level of significance were found for amplitude and area 
variables, for NCV variables this could be confirmed with a negligible exception for NCV1/2. 
The quotient evaluation showed in contrast to the results of N. tibialis significant results only 
for interval quotients (QIL13, QIL14), all other parameters remained with non-significant re-
sults. The observed shift from non-significant results for single interval variables to significant 
results in quotient intervals has been demonstrated also in the results of N. medianus and N. 
tibialis. These results indicate, that the for N. peronaeus variable quotients are not useful fro 
the differentiation between patient group 1 and 2 (exception: interval quotients). 
10. DISCUSSION 
As already discussed in the section 4. (Diagnosis of diabetic neuropathies [4]) the measure-
ments used to diagnose DNP vary widely and are still in discussion. In clinical routine the 
items tested for diagnosis of DNP may be different from the items tested e.g. in clinical re-
search projects. For daily practice of diagnostic tools tests applied shall ideally fulfill the fol-
lowing standards: 
1) Easy to apply with low effort in time, 
2) low inter-observer variation, 
3) good correlation with clinical progress of the disease, and 
4) non-invasive to the patient with a low risk profile. 
The application of peripheral motor nerve conduction testing was proven to serve these 
standards and is used widely by neurologists, where patients with suspicion of DNP are 
commonly diagnosed and treated. The advantages of this diagnostic tool has led to the fur-
ther developments for the purpose of diagnosis of different peripheral nerve disorders (23). 
Nevertheless the evaluations carried out in this study comparing this two patient groups con-
sisting of either normal subjects or patients suspicious of having DNP were not conducted 
yet. The advantages described above for nerve conduction studies qualify this method to be 
used for the diagnosis of DNP. Due to the fact, that in DNP nerve fibers of all diameters are 
affected (16) and a correlation exists between duration of diabetes mellitus and the progress 
of nerve conduction slowing in diabetic patients (1) this method should be also applicable to 
detect early changes of the peripheral nervous system in diabetic patients. It is well known, 
that the evaluation of nerve conduction velocity in peripheral nerves characterizes only the 
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nerve fibers with the fastest conduction velocities, this test has only limited evidence for the 
testing and evaluation of peripheral nerves (41). Indeed the underlying pathogenesis of DNP 
is still in discussion, both axonal degeneration and demyelinisation are probably involved in 
different stages of the disease (37). Therefore this study aims to characterize the function of 
motoric peripheral nerves to probably identify a demyelinisation process or axonal degenera-
tion or both in diabetic patients. To further evaluate the nerve function in terms of conduction 
velocity the characteristics of the compound muscle action potential shall be analyzed mean-
ing, that beyond the maximum nerve conduction velocity also the derived nerve conduction 
velocities of the characteristic biphasic compound muscle action potential shall be analyzed, 
which were defined to be NCV 2 to 4 (see 8.2). With this measure also nerve fibers repre-
senting slower conduction velocities shall be analyzed. Possible axonal degeneration shall 
be evaluated by testing the different amplitudes of the CMAP (maximum, positive amplitude, 
negative amplitude) for distal and proximal stimulation. Usually the area under the curve, 
which represents the quantity of nerve fibers stimulated, is almost comparable for distal and 
proximal stimulation in normal subjects (24). If a process like axonal degeneration occurs in 
DNP, then usually nerve fibers “die back” meaning that beginning with the distal end of the 
nerve fibers the degenerative process starts moving forward to proximal segments. This 
process should therefore not influence the quantity of nerve fibers stimulated, so that that for 
supramaximum stimulation the area under the curve is almost comparable both for distal and 
proximal stimulation. This issue could be identified by calculation of quotients derived from 
distal and proximal areas. In general the calculation of quotients for the variables amplitudes 
and intervals could serve to characterize the dispersion of the CMAP from distal to proximal 
stimulation, which could be explained by the diverse conduction of different nerve fibers 
within the peripheral nerve, which is naturally more pronounced for longer distances meaning 
proximal stimulation compared to distal stimulation. This dispersion mechanism will be ana-
lyzed by calculation of the quotients of amplitudes and intervals from distal to proximal stimu-
lation.  
All parameters tested are summarized in the following section. Results were categorized as 
following: 
1. distal parameters (intervals, amplitudes areas) 
2. proximal parameters (Intervals, amplitudes, areas) 
3. nerve conduction velocities (maximum nerve conduction velocity = NCV1 and follow-
ing nerve conduction velocities = NCV 2-4) 
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4. quotient parameters (interval quotients, amplitude quotients, area quotients). Parame-
ters were calculated by following equation: quotient = proximal variable / distal vari-
able (see 8.2). 
At the end of this part the results will be then be discussed and interpreted in comparison to 
other published data. 
 
Distal Parameter 
N. medianus 
Test Statisticsa
570,000 595,500 398,000 454,000 390,500 435,500 448,500
2848,000 766,500 569,000 625,000 561,500 606,500 619,500
-,355 -,081 -2,205 -1,603 -2,286 -1,728 -1,586
,723 ,936 ,027 ,109 ,022 ,084 ,113
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
N. tibialis 
Test Statisticsa
556,500 573,000 223,000 188,000 202,500 213,000 215,500
2834,500 2851,000 413,000 378,000 392,500 403,000 405,500
-,833 -,661 -4,305 -4,669 -4,518 -4,367 -4,341
,405 ,509 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
N. peronaeus 
Test Statisticsa
415,500 427,000 123,000 194,000 130,000 104,000 132,500
535,500 547,000 243,000 314,000 250,000 224,000 252,500
-1,044 -,906 -4,552 -3,701 -4,468 -4,754 -4,408
,297 ,365 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
The results obtained with regard to distal parameters (intervals, amplitudes, areas) showed 
for all three peripheral nerves similar results. The evaluation of both leg nerves (N. tibialis, N. 
peronaeus) resulted in highly significant differences for all amplitude and area variables, 
whereas for intervals the differences did not achieve a significant level. The results obtained 
for N. medianus were only significant for the positive and maximum amplitude, all other pa-
rameters did not reach significant levels. 
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Proximal parameter 
N. medianus 
Test Statisticsa
527,000 558,500 351,500 382,500 353,000 386,500 412,500
2805,000 2836,500 522,500 553,500 524,000 557,500 583,500
-,818 -,479 -2,705 -2,372 -2,689 -2,262 -1,979
,413 ,632 ,007 ,018 ,007 ,024 ,048
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
N. tibialis 
Test Statisticsa
454,500 483,500 148,500 170,000 164,000 173,000 196,000
2732,500 2761,500 338,500 360,000 354,000 363,000 386,000
-1,895 -1,593 -5,080 -4,856 -4,919 -4,789 -4,547
,058 ,111 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
N. peronaeus 
Test Statisticsa
502,000 483,000 123,500 115,000 114,500 106,000 125,000
622,000 603,000 243,500 235,000 234,500 226,000 245,000
-,006 -,234 -4,546 -4,648 -4,654 -4,730 -4,499
,995 ,815 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
Proximal parameters (intervals, amplitudes, areas) were tested similar compared to distal pa-
rameters. All amplitude and area variables showed significant levels, this result was also ob-
tained for N. medianus (here significant results, in N. tibialis respectively N. peronaeus 
highly-significant results). For intervals non-significant results were identified.  
 
Nerve conduction velocities 
N. medianus 
Test Statisticsa
256,500 252,500 197,000 234,000
427,500 423,500 368,000 405,000
-3,728 -3,770 -4,368 -3,970
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
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N. tibialis 
Test Statisticsa
133,500 75,000 76,500 99,500
323,500 265,000 266,500 289,500
-5,237 -5,845 -5,829 -5,590
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
N. peronaeus 
Test Statisticsa
276,500 225,000 203,000 206,500
396,500 345,000 323,000 326,500
-2,711 -3,328 -3,592 -3,550
,007 ,001 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
The evaluation of the differences of nerve conduction velocities in both patient groups re-
sulted in a quite homogenous setting: beside NCV 1 and NCV 2 in N. peronaeus all other 
nerve conductions showed highly significant differences between the two patient groups, 
NCV 1 and NCV 2 of N. peronaeus were significantly different in the patient groups.  
 
Quotient parameter 
N. medianus 
Test Statisticsa
447,500 384,000 359,000 343,000 323,000 321,000 370,000
2725,500 2662,000 530,000 514,000 494,000 492,000 541,000
-1,673 -2,356 -2,625 -2,797 -3,012 -2,976 -2,442
,094 ,018 ,009 ,005 ,003 ,003 ,015
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
N. tibialis 
Test Statisticsa
372,000 407,000 213,000 519,500 264,000 351,000 400,000
2650,000 2685,000 403,000 709,500 454,000 541,000 590,000
-2,753 -2,389 -4,408 -1,218 -3,877 -2,911 -2,395
,006 ,017 ,000 ,223 ,000 ,004 ,017
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
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N. peronaeus 
Test Statisticsa
219,000 256,500 351,500 432,500 345,500 477,500 374,500
2497,000 2534,500 471,500 552,500 465,500 597,500 494,500
-3,400 -2,951 -1,811 -,840 -1,883 -,213 -1,465
,001 ,003 ,070 ,401 ,060 ,832 ,143
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
The test results obtained for interval quotients showed all nerves and variables (exception: 
interval quotient QIL13 of N. medianus) significant differences between group 1 and group 2. 
The same result was achieved in the evaluation of the amplitude quotients for N. medianus 
and N. tibialis (exception negative amplitude quotient QA14 of N. tibialis). For N. peronaeus 
slightly different results were obtained, the significant level for the positive (QA12) and maxi-
mum amplitude (QA24) was not reached (p=0.07 respectively p=0.06) or not reached at all 
(Quotient negative amplitude QA14) similar to the results of the negative amplitude of N. tibi-
alis (QA14). The quotient parameters (quotient area 13 QAR13 and quotient area 14 QAR14) 
for the areas tested were significant for N. medianus and N. tibialis, whereas in N. peronaeus 
non-significant results were obtained.  
For the analysis of these results following different pathophysiological mechanisms could be 
involved: 
1. axonal degeneration leading to a general reduction of the amplitude of the compound 
muscle action potential (both proximal and distal) and/or 
2. demyelinisation leading to a reduction of nerve conduction velocities and a pro-
nounced dispersion of the compound muscle action potential (from distal to proximal 
stimulation). 
The results obtained for the changes of amplitudes indicate, that the patients in group 2 with 
diabetes have for almost all amplitude parameters significant or even highly significant lower 
values compared to normal subjects. These findings were more pronounced in leg nerves, 
but also for N. medianus significant changes were demonstrable. As possible explanation of 
these findings axonal degeneration could explain these results. The changes of amplitudes 
from distal to proximal stimulation, as analyzed by the quotient calculation, showed similar 
results. In general the decrease of amplitude from distal to proximal stimulation is related to 
the dispersion of the compound muscle action potential. It seems to be, that in diabetic pa-
tients this effect is more pronounced than in normal subjects. Interestingly the differences of 
single intervals variables do not reach significant levels for the two patient groups, obviously 
the deviation of these variables is to high to reach this level. But the change of these pa-
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rameters from distal to proximal stimulation, as tested by the quotient calculation, reaches 
significant levels (exception: quotient QIL13 of N. medianus). This indicates, that also for this 
parameter of dispersion differences exist between the two patient groups. The evaluation of 
changes of areas from distal to proximal stimulation provide similar results, nevertheless the 
results obtained for N. peronaeus did not reach significant levels. The changes of nerve con-
duction velocities provide in most cases (exception: NCV1/NCV2 of N. peronaeus) highly 
significant results between the patient groups. These changes indicate, that in diabetic pa-
tients obviously a demyelinisation process is involved.  
11. CONCLUSION 
As defined in the section 6. Aim of the study (6) the zero-hypothesis of this study was that 
parameters beside the standard parameters are not able to differentiate with significant re-
sults between the two patient groups in order to proof, whether other as standard variables 
can differentiate between these two patient groups. 
The standard parameters usually applied for the neurophysiological testing in patients suspi-
cious of having diabetic neuropathy are maximum nerve conduction velocity (NCV1) and the 
amplitude of the compound muscle action potential (A24). In addition to these parameters in 
this study further variables so as  
1) nerve conduction velocities (NCV 2, 3, 4),  
2) different parts of the amplitude (positive part=amplitude A12, negative ampli-
tude=A14),  
3) intervals (interval 13=IL13 and 14=IL14),  
4) areas (area 13=AR13 and 14=AR14), and  
5) quotients of these variables (quotient of intervals 13=QIL13 and 14=QIL14; quo-
tients of amplitudes A12=QA12, A14=QA14, A24=QA24; quotients of areas 
13=QAR13 and 14=QAR14) (see also 8.2) 
were analyzed and evaluated. 
The results obtained for nerve conduction velocities were all statistical significant different for 
the patient groups tested. This finding was demonstrated both for the conventional meaning 
maximum nerve conduction velocity (NCV1) as well as for the other nerve conduction veloci-
ties (NCV2, 3, 4). 
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The evaluation for amplitude parameters showed statistical significant differences for almost 
all tested variable (both maximum amplitudes as well as positive/negatives amplitudes), only 
the negative amplitude of  N. medianus showed non-significant results.  
The changes of intervals were tested with non-significant results for all variables. 
Almost all area variables were tested to be statistical significant different (exception: distal 
area 13 DAR13 and 14 DAR14 of N. medianus) between the two patient groups. 
Quotient variables were mostly tested with significant differences (exception: quotient interval 
13 [QIL13] N. medianus; quotient negative amplitude A14 [QA14] N. tibialis; quotient positive 
amplitude A12 [QA12] N. peronaeus; quotient negative amplitude A14 [QA14] N. peronaeus; 
quotient maximum amplitude A24 [QA24] N. peronaeus; quotient area 13 [QAR13] and 14 
[QAR14] N. peronaeus). 
These findings summarized can be interpreted that way, that in this study beside the stan-
dard variables, which achieved significant levels of differences in all tested peripheral nerves 
and items, also most of other parameters achieved this level of difference with the exception 
of interval variables and some others. In general the findings correlate well with the results of 
other publications (23). In addition the findings for N. medianus provide some hints, that for 
this peripheral nerve, which is usually affected in later stages of DNP, the progression of de-
myelinisation was more advanced than the axonal degeneration. The findings in both leg 
nerves did not demonstrate this difference, here both axonal degeneration and demyelinisa-
tion were similar advanced.  
The limitation of the testing carried out in this study is related to different items: 
1) the average age of the two groups tested differed, in group 2 the average age 
was 68 (±17 years), whereas in group 1 the average age was 49 years (±28 
years). In general it is known, that age influences nerve conduction velocities (36) 
and the amplitude of the compound muscle action potential (24). Both parameters 
have a tendency to decrease with increasing age. 
2) the number of patients investigated was different (group 1: n=67, group 2: n=21). 
3) the average time (±SD) elapsed since diagnosis of impaired glucose tolerance or 
manifest diabetes mellitus in group 2 was 12,1 years ( ±7.3 ys), therefore in some 
patients the metabolic disorder and related diseases could be more advanced. 
4) patients with either impaired glucose tolerance or manifest diabetes mellitus were 
included, as a consequence different stages of severity of the underlying disease 
will influence the analysis of the data. 
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All together it seems to be, that the parameters tested could be helpful to be further investi-
gated in studies, which aim to solve the problems as mentioned above in order to improve 
the differentiation of normal subjects and patients in early stages of diabetes mellitus or im-
paired glucose tolerance. 
12. SUMMARY 
Diabetic neuropathy is a frequent complication of patients suffering from diabetes mellitus 
(either type I or type II diabetes). The clinical picture of this disease varies widely from non-
symptomatic courses to severe disabling and potential life-threatening cases, mostly due to 
autonomic neuropathy. The treatment of diabetic neuropathy is despite huge investments in 
clinical research mostly related to an effective control of blood glucose levels. Beside acute 
courses of diabetic neuropathy, which tend to remit, most patients suffer from chronic 
courses of diabetic neuropathy, where distal symmetric neuropathy is the most common 
course of disease. These cases are usually chronic progressive, therefore early diagnosis 
and intervention is mandatory. The advantages of neurographic testing as diagnostic tool in 
terms of reliability, validity, relevance, and patient’s safety is well accepted. Used by medical 
professionals this method provides information about the functional status of the peripheral 
nervous system. This study was conducted comparing normal subjects and patients with 
diabetes mellitus or impaired glucose tolerance, who with suspicion of diabetic neuropathy. 
The aim of this study was to identify additional neurographic markers who can differentiate 
between the two patient groups in order to possibly provide a diagnostic tool for the early di-
agnosis of diabetic neuropathy. These markers should supplement the markers already es-
tablished so as maximum nerve conduction velocity or amplitude of the compound muscle 
action potential. The evaluation of further markers so as further conduction velocities, posi-
tive/negative amplitudes, quotients of intervals/amplitudes/areas revealed significant differ-
ences between the two patient groups, nevertheless also the standard markers demon-
strated significant differences. These findings could be related to the fact, that the average 
age in group 2 with diabetic patients was substantially higher than in group 1 with normal 
subjects. In addition the progression of diabetic neuropathy could be more advanced, so that 
an additional study with patients in an earlier stage of disease and comparable age could im-
prove the diagnosis of early diabetic neuropathy. 
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13. ATTACHMENT 
In the following section the detailed data analyzed are displayed. The sequence of the data 
presented is as following: first the data of N. medianus are presented, followed by N. tibialis 
and N. peronaeus. Within the section of each nerve following order is given: first distal pa-
rameters are displayed, followed by proximal parameters, NCVs and quotients. Within these 
sections first the results of the descriptive statistics (n, mean, median, standard deviation, 
minimum, maximum, percentiles 25/5075) are displayed, followed by the results of the non-
parametric test (NPar test, Mann-Whitney tests) and the boxplots. 
13.1 Listing of tables/boxplots 
13.1.1 N. medianus 
13.1.1.1 Distal parameter 
Frequencies 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,017 7,37 7,8699 4,9260 12,78 22,980 33,980
5,000 7,35 7,5000 4,7600 12,30 21,900 32,450
,6887 1,345 2,83707 2,09891 4,751 9,1661 14,6886
3,0 4 3,22 1,70 6 6,9 10,9
6,5 11 15,80 10,80 27 51,5 84,6
4,650 6,25 5,8500 3,1200 8,86 16,000 22,625
5,000 7,35 7,5000 4,7600 12,30 21,900 32,450
5,450 8,40 10,0000 6,2600 15,80 28,700 41,050
18 18 18 18 18 18 18
0 0 0 0 0 0 0
5,133 7,28 6,2122 3,9822 10,18 18,567 27,683
5,250 7,24 5,6850 3,5100 8,76 17,750 26,450
1,1594 1,661 2,81814 1,39614 3,998 8,5231 11,5875
3,3 5 2,14 2,16 6 4,2 9,4
7,2 10 12,30 6,88 19 33,3 49,2
4,150 5,71 4,2925 3,0675 6,92 12,425 19,650
5,250 7,24 5,6850 3,5100 8,76 17,750 26,450
5,950 8,86 7,8650 4,8950 12,00 24,700 39,050
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 42,51 2848,00
18 44,83 807,00
85
67 43,11 2888,50
18 42,58 766,50
85
67 46,06 3086,00
18 31,61 569,00
85
67 45,22 3030,00
18 34,72 625,00
85
67 46,17 3093,50
18 31,19 561,50
85
66 44,90 2963,50
18 33,69 606,50
84
66 44,70 2950,50
18 34,42 619,50
84
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
DIL13
DIL14
DA12
DA14
DA24
DAR13
DAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
570,000 595,500 398,000 454,000 390,500 435,500 448,500
2848,000 766,500 569,000 625,000 561,500 606,500 619,500
-,355 -,081 -2,205 -1,603 -2,286 -1,728 -1,586
,723 ,936 ,027 ,109 ,022 ,084 ,113
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
 
 
Boxplots distal interval 13 (DIL13) 
 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots distal interval 14 (DIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1867N =
GR
21
D
IL
14
12
11
10
9
8
7
6
5
4
3
 
 
 
Boxplots distal amplitude 12 (DA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DA12
N Percent N Percent N Percent
Valid Missing Total
Cases
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18
16
14
12
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8
6
4
2
0
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14
 
 
 
Boxplots distal amplitude 14 (DA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DA14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1867N =
GR
21
D
A1
4
12
10
8
6
4
2
0
 
 
 
Boxplots distal amplitude 24 (DA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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14
 
 
 
Boxplots distal area 13 (DAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1866N =
GR
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D
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13
60
50
40
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14
 
 
 
Boxplots distal area 14 (DAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
DAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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13.1.1.2 Proximal parameter 
Frequencies 
 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,288 7,6742 7,3348 4,6373 11,9579 22,076 33,014
5,220 7,4500 6,9300 4,5300 11,4000 20,450 31,100
,7268 1,38581 2,77287 2,02051 4,61871 8,9825 14,4639
3,4 4,59 2,77 1,26 4,96 6,7 10,9
6,8 10,90 14,80 10,20 25,00 50,4 81,9
4,800 6,5000 5,1200 3,0400 7,8900 15,775 21,975
5,220 7,4500 6,9300 4,5300 11,4000 20,450 31,100
5,800 8,8000 8,6100 6,0500 14,9000 27,200 41,375
18 18 18 18 18 18 18
0 0 0 0 0 0 0
5,565 7,7328 5,4172 3,3639 8,7833 16,644 25,089
5,600 7,7500 4,8800 2,9500 7,8350 15,550 23,400
1,1493 1,63450 2,27654 1,22753 3,36214 6,8891 9,9525
3,3 4,59 1,80 1,32 4,34 3,5 7,8
7,4 10,10 10,90 6,20 17,10 29,5 40,2
4,635 6,2125 3,5125 2,5900 6,1050 10,950 18,250
5,600 7,7500 4,8800 2,9500 7,8350 15,550 23,400
6,400 9,1250 6,6525 4,6200 11,0750 23,925 34,925
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 41,87 2805,00
18 47,22 850,00
85
67 42,34 2836,50
18 45,47 818,50
85
67 46,75 3132,50
18 29,03 522,50
85
67 46,29 3101,50
18 30,75 553,50
85
67 46,73 3131,00
18 29,11 524,00
85
66 45,64 3012,50
18 30,97 557,50
84
66 45,25 2986,50
18 32,42 583,50
84
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
PIL13
PIL14
PA12
PA14
PA24
PAR13
PAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
527,000 558,500 351,500 382,500 353,000 386,500 412,500
2805,000 2836,500 522,500 553,500 524,000 557,500 583,500
-,818 -,479 -2,705 -2,372 -2,689 -2,262 -1,979
,413 ,632 ,007 ,018 ,007 ,024 ,048
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
 
Boxplots proximal interval 13 (PIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal interval 14 (PIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1867N =
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10
9
8
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5
4
 
 
 
Boxplots proximal amplitude 12 (PA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PA12
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
Page 66 
  
1867N =
GR
21
P
A
12
16
14
12
10
8
6
4
2
0
14
 
 
 
Boxplots proximal amplitude 14 (PA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PA14
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal amplitude 24 (PA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal area 13 (PAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal area 14 (PAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
PAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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13.1.1.3 Nerve conduction velocities 
Frequencies 
 
Statistics
67 67 67 67
0 0 0 0
55,042 51,554 51,890 51,325
54,700 51,250 51,813 50,000
3,2557 4,2265 3,7460 4,4752
50,0 36,1 44,1 44,2
63,2 59,0 60,0 60,9
52,400 50,000 49,425 47,778
54,700 51,250 51,813 50,000
57,500 54,118 54,324 55,128
18 18 18 18
0 0 0 0
51,074 48,055 46,676 46,319
51,300 46,488 46,584 46,212
4,0414 5,4030 3,8681 4,0528
44,6 39,8 38,8 41,0
59,7 61,2 55,4 56,5
47,095 45,430 44,615 43,904
51,300 46,488 46,584 46,212
52,750 49,447 48,570 48,778
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
NCV1 NCV2 NCV3 NCV4
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NPar Tests 
Mann-Whitney Test 
Ranks
67 48,17 3227,50
18 23,75 427,50
85
67 48,23 3231,50
18 23,53 423,50
85
67 49,06 3287,00
18 20,44 368,00
85
67 48,51 3250,00
18 22,50 405,00
85
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
NCV1
NCV2
NCV3
NCV4
N Mean Rank Sum of Ranks
 
Test Statisticsa
256,500 252,500 197,000 234,000
427,500 423,500 368,000 405,000
-3,728 -3,770 -4,368 -3,970
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
 
 
Boxplots nerve conduction velocity 1 (NCV1) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
NCV1
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots nerve conduction velocity 2 (NCV2) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
NCV2
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots nerve conduction velocity 3 (NCV3) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
NCV3
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots nerve conduction velocity 4 (NCV4) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
NCV4
N Percent N Percent N Percent
Valid Missing Total
Cases
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21
N
C
V4
70
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13.1.1.4 Quotient parameter 
Frequencies 
 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
1,05529 1,04219 ,92811 ,93905 ,93182 ,96030 ,97063
1,04211 1,03125 ,93430 ,94857 ,94309 ,96900 ,97370
,047380 ,035061 ,050959 ,085285 ,047485 ,051921 ,046301
1,008 1,005 ,788 ,642 ,823 ,804 ,852
1,283 1,179 1,033 1,109 1,000 1,092 1,088
1,02366 1,01563 ,89956 ,89850 ,89015 ,92636 ,93904
1,04211 1,03125 ,93430 ,94857 ,94309 ,96900 ,97370
1,06757 1,05882 ,96964 ,99194 ,97226 ,99200 1,00000
18 18 18 18 18 18 18
0 0 0 0 0 0 0
1,09026 1,06661 ,89776 ,84761 ,86834 ,92914 ,91527
1,07966 1,06029 ,87803 ,88768 ,88422 ,91220 ,92857
,072422 ,045386 ,148667 ,137705 ,082897 ,166347 ,084593
1,007 1,016 ,689 ,597 ,713 ,733 ,748
1,265 1,163 1,410 1,108 ,987 1,527 1,024
1,02494 1,02731 ,83770 ,74206 ,79969 ,85286 ,83583
1,07966 1,06029 ,87803 ,88768 ,88422 ,91220 ,92857
1,13557 1,09458 ,93498 ,95427 ,93278 ,96542 ,98835
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 40,68 2725,50
18 51,64 929,50
85
67 39,73 2662,00
18 55,17 993,00
85
67 46,64 3125,00
18 29,44 530,00
85
67 46,88 3141,00
18 28,56 514,00
85
67 47,18 3161,00
18 27,44 494,00
85
66 46,64 3078,00
18 27,33 492,00
84
66 45,89 3029,00
18 30,06 541,00
84
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
QIL13
QIL14
QA12
QA14
QA24
QAR13
QAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
447,500 384,000 359,000 343,000 323,000 321,000 370,000
2725,500 2662,000 530,000 514,000 494,000 492,000 541,000
-1,673 -2,356 -2,625 -2,797 -3,012 -2,976 -2,442
,094 ,018 ,009 ,005 ,003 ,003 ,015
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
 
Boxplots interval quotient 13 (QIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
 
Page 73 
  
1867N =
GR
21
Q
IL
13
1,4
1,3
1,2
1,1
1,0
,9
641
48
 
 
 
Boxplots interval quotient 14 (QIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots amplitude quotient 12 (QA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QA12
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots amplitude quotient 14 (QA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QA14
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots amplitude quotient 24 (QA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots area quotient 13 (QAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
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QAR13
N Percent N Percent N Percent
Valid Missing Total
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Boxplots area quotient 14 (QAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
18 100,0% 0 ,0% 18 100,0%
GR
1
2
QAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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13.1.2 N. tibialis 
13.1.2.1 Distal parameter 
Frequencies 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,3430 6,8145 11,6709 8,2160 19,891 27,435 45,391
5,2500 6,6500 11,0000 7,6100 19,000 27,950 44,350
1,11396 1,34313 4,91186 3,75073 8,3805 11,2668 19,7011
3,60 4,53 4,04 1,46 6,3 9,7 14,9
8,65 10,70 27,50 18,60 45,8 65,6 105,1
4,4700 5,7600 8,7400 5,5100 15,500 17,950 28,225
5,2500 6,6500 11,0000 7,6100 19,000 27,950 44,350
5,8000 7,5500 13,9000 10,1000 23,500 33,925 59,100
19 19 19 19 19 19 19
0 0 0 0 0 0 0
5,4621 6,8863 6,4437 3,9626 10,406 15,061 24,084
5,8000 7,3000 5,3700 3,3000 8,920 12,400 18,700
1,14750 1,33900 3,63909 2,17345 5,5975 7,9382 12,7965
3,05 3,95 1,97 1,28 3,3 5,0 7,9
7,40 8,65 15,20 10,20 25,4 35,7 51,5
4,5000 5,7000 4,0400 2,9800 7,300 10,100 15,700
5,8000 7,3000 5,3700 3,3000 8,920 12,400 18,700
6,3600 7,9800 6,7100 4,2100 10,900 17,700 31,300
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 42,31 2834,50
19 47,71 906,50
86
67 42,55 2851,00
19 46,84 890,00
86
67 49,67 3328,00
19 21,74 413,00
86
67 50,19 3363,00
19 19,89 378,00
86
67 49,98 3348,50
19 20,66 392,50
86
66 49,27 3252,00
19 21,21 403,00
85
66 49,23 3249,50
19 21,34 405,50
85
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
DIL13
DIL14
DA12
DA14
DA24
DAR13
DAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
556,500 573,000 223,000 188,000 202,500 213,000 215,500
2834,500 2851,000 413,000 378,000 392,500 403,000 405,500
-,833 -,661 -4,305 -4,669 -4,518 -4,367 -4,341
,405 ,509 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
 
 
Boxplots distal interval 13 (DIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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1967N =
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10
9
8
7
6
5
4
3
2
460
58
 
 
 
Boxplots distal interval 14 (DIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
D
IL
14
12
10
8
6
4
2
58
 
 
 
Boxplots distal amplitude 12 (DA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DA12
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
Page 79 
  
1967N =
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D
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2
30
20
10
0
7582
7069
6
9
447
 
 
 
Boxplots distal amplitude 14 (DA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DA14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
D
A1
4
30
20
10
0
-10
846
82
70
69
207
44
 
 
 
Boxplots distal amplitude 24 (DA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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30
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10
0
82
70
69
9
7
44
 
 
 
Boxplots distal area 13 (DAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1966N =
GR
21
D
AR
13
70
60
50
40
30
20
10
0
69
70
7
 
 
 
Boxplots distal area 14 (DAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
DAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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13.1.2.2 Proximal parameter 
Frequencies 
 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,951 7,7475 9,1939 6,8522 16,032 24,633 42,088
5,800 7,3500 8,7400 6,3400 15,300 23,650 39,150
1,1818 1,54679 4,16957 3,19513 7,2051 10,4426 19,0208
4,0 5,22 3,18 1,97 5,5 9,7 15,1
9,2 12,40 23,40 16,40 39,3 59,5 104,0
5,090 6,6500 6,4900 4,8800 11,400 16,425 27,350
5,800 7,3500 8,7400 6,3400 15,300 23,650 39,150
6,500 8,6000 10,8000 8,3400 18,100 31,250 53,700
19 19 19 19 19 19 19
0 0 0 0 0 0 0
6,508 8,3237 4,1447 3,1842 7,330 12,015 20,900
6,700 8,6000 3,2400 3,0800 5,560 10,000 17,100
1,2199 1,51063 2,67796 1,81930 4,2744 7,4015 12,0788
4,3 5,75 1,03 ,87 1,9 3,2 6,1
8,9 10,60 11,80 8,69 18,3 32,9 49,6
5,550 7,0500 2,4800 1,7700 4,820 7,100 14,700
6,700 8,6000 3,2400 3,0800 5,560 10,000 17,100
7,350 9,5000 5,0700 3,8500 8,920 13,800 27,800
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 40,78 2732,50
19 53,08 1008,50
86
67 41,22 2761,50
19 51,55 979,50
86
67 50,78 3402,50
19 17,82 338,50
86
67 50,46 3381,00
19 18,95 360,00
86
67 50,55 3387,00
19 18,63 354,00
86
66 49,88 3292,00
19 19,11 363,00
85
66 49,53 3269,00
19 20,32 386,00
85
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
PIL13
PIL14
PA12
PA14
PA24
PAR13
PAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
454,500 483,500 148,500 170,000 164,000 173,000 196,000
2732,500 2761,500 338,500 360,000 354,000 363,000 386,000
-1,895 -1,593 -5,080 -4,856 -4,919 -4,789 -4,547
,058 ,111 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
 
Boxplots proximal interval 13 (PIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal interval 14 (PIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
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P
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14
12
10
8
6
4
3
58
 
 
 
Boxplots proximal amplitude 12 (PA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PA12
N Percent N Percent N Percent
Valid Missing Total
Cases
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69
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Boxplots proximal amplitude 14 (PA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PA14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
P
A
14
20
10
0
-10
69
20
744
 
 
 
Boxplots proximal amplitude 24 (PA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal area 13 (PAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1966N =
GR
21
P
A
R
13
70
60
50
40
30
20
10
0
-10
69
70
7
 
 
 
Boxplots proximal area 14 (PAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
PAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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20
0
-20
70
69
7
 
13.1.2.3 Nerve conduction velocities 
Frequencies 
 
Statistics
67 67 67 67
0 0 0 0
46,767 44,852 43,766 42,263
46,300 45,181 43,925 42,135
3,7759 3,4908 3,3977 3,5518
40,2 37,1 36,2 34,6
58,7 53,0 52,6 51,6
44,200 41,954 41,243 39,583
46,300 45,181 43,925 42,135
49,200 47,552 46,429 44,565
19 19 19 19
0 0 0 0
40,633 37,307 35,924 34,808
39,700 37,500 36,816 34,649
3,4773 3,8196 3,9460 4,5147
33,3 27,9 26,1 25,3
47,9 43,6 42,3 43,1
38,100 34,335 32,922 32,323
39,700 37,500 36,816 34,649
43,700 40,212 37,615 37,931
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
NCV1 NCV2 NCV3 NCV4
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NPar Tests 
Mann-Whitney Test 
Ranks
67 51,01 3417,50
19 17,03 323,50
86
67 51,88 3476,00
19 13,95 265,00
86
67 51,86 3474,50
19 14,03 266,50
86
67 51,51 3451,50
19 15,24 289,50
86
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
NCV1
NCV2
NCV3
NCV4
N Mean Rank Sum of Ranks
 
Test Statisticsa
133,500 75,000 76,500 99,500
323,500 265,000 266,500 289,500
-5,237 -5,845 -5,829 -5,590
,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
 
 
Boxplots nerve conduction velocity 1 (NCV1) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
NCV1
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
N
C
V1
70
60
50
40
30
1
21
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Boxplots nerve conduction velocity 2 (NCV2) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
NCV2
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
N
C
V2
60
50
40
30
20
78
 
 
 
Boxplots nerve conduction velocity 3 (NCV3) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
NCV3
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
N
C
V3
60
50
40
30
20
78
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Boxplots nerve conduction velocity 4 (NCV4) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
NCV4
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
N
C
V4
60
50
40
30
20
78
 
13.1.2.4 Quotient parameter 
Frequencies 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
1,11838 1,13914 ,78590 ,85298 ,80533 ,89857 ,92467
1,10476 1,12844 ,78276 ,84286 ,81722 ,88135 ,92903
,081415 ,078469 ,090501 ,158077 ,081334 ,084812 ,063385
1,009 1,021 ,557 ,569 ,624 ,734 ,792
1,400 1,352 ,959 1,658 ,994 1,110 1,064
1,05780 1,08738 ,71121 ,76951 ,72569 ,83659 ,87497
1,10476 1,12844 ,78276 ,84286 ,81722 ,88135 ,92903
1,17045 1,17706 ,84921 ,90520 ,86452 ,95994 ,97451
19 19 19 19 19 19 19
0 0 0 0 0 0 0
1,20453 1,22113 ,63304 ,80304 ,69317 ,78806 ,85935
1,18421 1,22100 ,61825 ,77850 ,66716 ,79661 ,88976
,125341 ,151356 ,119638 ,165933 ,103937 ,164497 ,144964
1,027 1,028 ,410 ,523 ,562 ,513 ,601
1,410 1,570 ,804 1,160 ,893 1,149 1,242
1,10000 1,13158 ,57051 ,68627 ,61104 ,65347 ,77215
1,18421 1,22100 ,61825 ,77850 ,66716 ,79661 ,88976
1,30097 1,31884 ,75559 ,95000 ,74890 ,92157 ,94857
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 39,55 2650,00
19 57,42 1091,00
86
67 40,07 2685,00
19 55,58 1056,00
86
67 49,82 3338,00
19 21,21 403,00
86
67 45,25 3031,50
19 37,34 709,50
86
67 49,06 3287,00
19 23,89 454,00
86
66 47,18 3114,00
19 28,47 541,00
85
66 46,44 3065,00
19 31,05 590,00
85
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
QIL13
QIL14
QA12
QA14
QA24
QAR13
QAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
372,000 407,000 213,000 519,500 264,000 351,000 400,000
2650,000 2685,000 403,000 709,500 454,000 541,000 590,000
-2,753 -2,389 -4,408 -1,218 -3,877 -2,911 -2,395
,006 ,017 ,000 ,223 ,000 ,004 ,017
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
 
Boxplots interval quotient 13 (QIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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1,5
1,4
1,3
1,2
1,1
1,0
,9
21
32
 
 
 
Boxplots interval quotient 14 (QIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
Q
IL
14
1,7
1,6
1,5
1,4
1,3
1,2
1,1
1,0
,9
84
75
21
32
 
 
 
Boxplots amplitude quotient 12 (QA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QA12
N Percent N Percent N Percent
Valid Missing Total
Cases
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A1
2
1,0
,9
,8
,7
,6
,5
,4
,3
 
 
 
Boxplots amplitude quotient 14 (QA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QA14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1967N =
GR
21
Q
A1
4
1,8
1,6
1,4
1,2
1,0
,8
,6
,4
58
30
 
 
 
Boxplots amplitude quotient 24 (QA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots area quotient 13 (QAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1966N =
GR
21
Q
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13
1,2
1,0
,8
,6
,4
 
 
 
Boxplots area quotient 14 (QAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
19 100,0% 0 ,0% 19 100,0%
GR
1
2
QAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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1,4
1,2
1,0
,8
,6
,4
68
 
 
13.1.3 N. peronaeus 
13.1.3.1 Distal parameter 
Frequencies 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,5094 7,245 6,5706 3,2210 9,78 19,817 27,159
5,4600 7,260 6,0700 3,0600 9,00 19,000 25,850
,88143 1,2844 1,75050 1,45370 2,867 5,2584 7,8019
3,48 4,2 3,71 ,96 5 10,9 15,6
7,50 10,0 11,10 8,49 18 31,8 45,2
5,0000 6,250 5,2900 2,0800 8,00 16,175 20,800
5,4600 7,260 6,0700 3,0600 9,00 19,000 25,850
6,2000 8,000 8,1000 3,8500 12,00 23,650 32,950
15 15 15 15 15 15 15
0 0 0 0 0 0 0
5,2940 6,887 3,6907 1,7687 5,46 10,689 15,040
4,9500 6,650 3,8300 1,8500 6,09 11,600 16,600
1,04427 1,5175 1,67409 ,89550 2,461 5,2371 6,9417
3,50 4,3 1,09 ,25 1 1,7 3,7
7,25 9,4 6,46 3,57 10 18,5 23,3
4,5500 5,900 1,7100 ,8300 3,35 4,700 8,600
4,9500 6,650 3,8300 1,8500 6,09 11,600 16,600
6,1500 7,800 4,9200 2,2800 6,60 15,600 21,500
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 42,80 2867,50
15 35,70 535,50
82
67 42,63 2856,00
15 36,47 547,00
82
67 47,16 3160,00
15 16,20 243,00
82
67 46,10 3089,00
15 20,93 314,00
82
67 47,06 3153,00
15 16,67 250,00
82
66 46,92 3097,00
15 14,93 224,00
81
66 46,49 3068,50
15 16,83 252,50
81
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
DIL13
DIL14
DA12
DA14
DA24
DAR13
DAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
415,500 427,000 123,000 194,000 130,000 104,000 132,500
535,500 547,000 243,000 314,000 250,000 224,000 252,500
-1,044 -,906 -4,552 -3,701 -4,468 -4,754 -4,408
,297 ,365 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
DIL13 DIL14 DA12 DA14 DA24 DAR13 DAR14
Grouping Variable: GRa. 
 
 
 
Boxplots distal interval 13 (DIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots distal interval 14 (DIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DIL14
N Percent N Percent N Percent
Valid Missing Total
Cases
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9
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3
 
 
 
Boxplots distal amplitude 12 (DA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DA12
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots distal amplitude 14 (DA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DA14
N Percent N Percent N Percent
Valid Missing Total
Cases
 
1567N =
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D
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4
10
8
6
4
2
0
-2
60
56
 
 
 
Boxplots distal amplitude 24 (DA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DA24
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots distal area 13 (DAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DAR13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots distal area 14 (DAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
2
DAR14
N Percent N Percent N Percent
Valid Missing Total
Cases
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13.1.3.2 Proximal parameter 
 
Frequencies 
 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
5,796 7,862 5,4410 3,2991 8,7306 17,321 25,156
5,900 7,950 5,2700 3,0700 8,3500 16,350 23,850
,8982 1,4543 1,53464 1,21714 2,57938 4,8279 7,5086
3,6 4,5 2,96 1,17 4,58 8,9 13,9
7,7 11,2 9,61 6,29 15,30 29,0 43,3
5,200 6,800 4,3700 2,4600 6,8700 13,800 18,975
5,900 7,950 5,2700 3,0700 8,3500 16,350 23,850
6,450 8,940 6,3400 3,8500 10,5000 20,625 30,700
15 15 15 15 15 15 15
0 0 0 0 0 0 0
5,916 7,814 2,9259 1,6759 4,6067 9,173 13,520
5,600 7,500 3,0200 1,6600 5,0500 9,300 14,200
1,0551 1,4779 1,56869 ,79860 2,24043 4,5456 6,5698
4,5 5,4 ,78 ,39 1,17 2,4 2,8
8,2 10,6 6,17 3,39 8,49 16,7 22,4
5,150 6,750 1,5000 1,1700 2,7500 4,600 8,000
5,600 7,500 3,0200 1,6600 5,0500 9,300 14,200
6,800 9,020 4,0400 2,3200 5,6100 12,600 19,200
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 41,51 2781,00
15 41,47 622,00
82
67 41,79 2800,00
15 40,20 603,00
82
67 47,16 3159,50
15 16,23 243,50
82
67 47,28 3168,00
15 15,67 235,00
82
67 47,29 3168,50
15 15,63 234,50
82
66 46,89 3095,00
15 15,07 226,00
81
66 46,61 3076,00
15 16,33 245,00
81
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
PIL13
PIL14
PA12
PA14
PA24
PAR13
PAR14
N Mean Rank Sum of Ranks
 
 
Test Statisticsa
502,000 483,000 123,500 115,000 114,500 106,000 125,000
622,000 603,000 243,500 235,000 234,500 226,000 245,000
-,006 -,234 -4,546 -4,648 -4,654 -4,730 -4,499
,995 ,815 ,000 ,000 ,000 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
PIL13 PIL14 PA12 PA14 PA24 PAR13 PAR14
Grouping Variable: GRa. 
 
 
 
Boxplots proximal interval 13 (PIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
GR
1
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PIL13
N Percent N Percent N Percent
Valid Missing Total
Cases
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Boxplots proximal interval 14 (PIL14) 
Case Processing Summary
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Boxplots proximal amplitude 12 (PA12) 
Case Processing Summary
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Boxplots proximal amplitude 14 (PA14) 
Case Processing Summary
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Boxplots proximal amplitude 24 (PA24) 
Case Processing Summary
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Boxplots proximal area 13 (PAR13) 
Case Processing Summary
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15 100,0% 0 ,0% 15 100,0%
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Boxplots proximal area 14 (PAR14) 
Case Processing Summary
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13.1.3.3 Nerve conduction velocities 
 
Frequencies 
Statistics
67 67 67 67
0 0 0 0
47,366 44,926 45,863 43,868
47,100 45,070 45,251 44,118
3,6696 3,5012 3,8954 3,6325
40,2 38,4 39,4 35,5
60,8 57,0 60,8 55,3
45,200 42,282 43,671 41,549
47,100 45,070 45,251 44,118
49,300 47,097 48,000 46,203
15 15 15 15
0 0 0 0
44,148 40,310 40,785 39,321
42,900 40,984 40,123 39,326
5,1543 4,7526 4,2500 4,3102
38,5 32,8 33,3 32,0
54,0 49,0 47,1 47,1
40,400 35,928 36,667 36,000
42,900 40,984 40,123 39,326
48,000 43,796 45,238 42,537
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
NCV1 NCV2 NCV3 NCV4
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NPar Tests 
Mann-Whitney Test 
Ranks
67 44,87 3006,50
15 26,43 396,50
82
67 45,64 3058,00
15 23,00 345,00
82
67 45,97 3080,00
15 21,53 323,00
82
67 45,92 3076,50
15 21,77 326,50
82
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
NCV1
NCV2
NCV3
NCV4
N Mean Rank Sum of Ranks
 
Test Statisticsa
276,500 225,000 203,000 206,500
396,500 345,000 323,000 326,500
-2,711 -3,328 -3,592 -3,550
,007 ,001 ,000 ,000
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
NCV1 NCV2 NCV3 NCV4
Grouping Variable: GRa. 
 
 
 
Boxplots nerve conduction velocity 1 (NCV1) 
Case Processing Summary
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Boxplots nerve conduction velocity (NCV2) 
Case Processing Summary
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Boxplots nerve conduction velocity 3 (NCV3) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Boxplots nerve conduction velocity 4 (NCV4) 
Case Processing Summary
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13.1.3.4 Quotient parameter 
 
Frequencies 
Statistics
67 67 67 67 67 66 66
0 0 0 0 0 1 1
1,05394 1,08469 ,82749 1,08361 ,89476 ,87623 ,92598
1,03704 1,07792 ,83000 1,05943 ,89583 ,86754 ,93624
,052025 ,055829 ,069999 ,237361 ,069759 ,094302 ,063965
,956 1,005 ,644 ,490 ,695 ,686 ,737
1,300 1,343 ,979 1,740 ,994 1,214 1,110
1,02222 1,04712 ,76485 ,89737 ,85248 ,81017 ,88715
1,03704 1,07792 ,83000 1,05943 ,89583 ,86754 ,93624
1,07073 1,10219 ,87573 1,24519 ,94761 ,93231 ,96960
15 15 15 15 15 15 15
0 0 0 0 0 0 0
1,12464 1,14437 ,77039 1,01911 ,84275 ,88587 ,88927
1,10599 1,13978 ,79310 ,99024 ,86866 ,85926 ,89720
,086778 ,083016 ,118368 ,254114 ,107221 ,169365 ,081453
1,014 1,012 ,554 ,473 ,566 ,676 ,747
1,304 1,337 ,955 1,542 ,988 1,387 ,995
1,05495 1,08631 ,71395 ,87547 ,80414 ,78378 ,83133
1,10599 1,13978 ,79310 ,99024 ,86866 ,85926 ,89720
1,16667 1,17460 ,85260 1,12973 ,92593 ,95775 ,97297
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
Valid
Missing
N
Mean
Median
Std. Deviation
Minimum
Maximum
25
50
75
Percentiles
GR
1
2
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
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NPar Tests 
Mann-Whitney Test 
Ranks
67 37,27 2497,00
15 60,40 906,00
82
67 37,83 2534,50
15 57,90 868,50
82
67 43,75 2931,50
15 31,43 471,50
82
67 42,54 2850,50
15 36,83 552,50
82
67 43,84 2937,50
15 31,03 465,50
82
66 41,27 2723,50
15 39,83 597,50
81
66 42,83 2826,50
15 32,97 494,50
81
GR
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
1
2
Total
QIL13
QIL14
QA12
QA14
QA24
QAR13
QAR14
N Mean Rank Sum of Ranks
 
Test Statisticsa
219,000 256,500 351,500 432,500 345,500 477,500 374,500
2497,000 2534,500 471,500 552,500 465,500 597,500 494,500
-3,400 -2,951 -1,811 -,840 -1,883 -,213 -1,465
,001 ,003 ,070 ,401 ,060 ,832 ,143
Mann-Whitney U
Wilcoxon W
Z
Asymp. Sig. (2-tailed)
QIL13 QIL14 QA12 QA14 QA24 QAR13 QAR14
Grouping Variable: GRa. 
 
 
 
Boxplots interval quotient 13 (QIL13) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Boxplots interval quotient 14 (QIL14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Boxplots amplitude quotient 12 (QA12) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Boxplots amplitude quotient 14 (QA14) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Valid Missing Total
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Boxplots amplitude quotient 24 (QA24) 
Case Processing Summary
67 100,0% 0 ,0% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Valid Missing Total
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Boxplots area quotient 13 (QAR13) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
15 100,0% 0 ,0% 15 100,0%
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Boxplots area quotient 14 (QAR14) 
Case Processing Summary
66 98,5% 1 1,5% 67 100,0%
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13.2 Ethical issues 
Acrobat-Dokumen
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13.3 Abbreviations 
A   amplitude 
ALS   amyotrophic lateral sclerosis 
AR   area 
ARI   aldose reductase inhibitor 
ATR   achilles tendon reflex 
CAFT   cardiovascular autonomic function testing 
CI   confidence interval 
CIPD   chronic inflammatory demyelinating polyneuropathy 
CMAP   compound muscle action potential 
d   distal (as prefix) 
DCCT   diabetes control and complication trial 
DM   diabetes mellitus 
DNES   diabetic neuropathy examination score 
DNP   diabetic neuropathy 
DNS   diabetic neuropathy score 
DS   distal stimulus 
DSP   distal symmetric polyneuropathy 
EDS   electro-diagnostic study 
GR   group 
IDDM   insulin-dependent diabetes mellitus 
IGT   impaired glucose tolerance 
IL   interval 
mA   milliampere 
mm   millimeter 
mNCV   motor nerve conduction velocity 
ms   milliseconds 
mV   millivolt 
N.   nervus 
NCS   nerve conduction study 
NCV   nerve conduction velocity 
ND   neuropathic deficit 
n.k.   not known 
NIDDM  non-insulin-dependent diabetes mellitus 
No.   number 
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NPar Tests  non-parametric tests 
NS   neuropathic symptoms 
p   proximal (as prefix) 
PNS   peripheral nervous system 
PS   proximal stimulus 
PTR   patella tendon reflex 
Q   quotient 
QAFT   quantitative autonomic function test 
QST   quantitative sensory test 
SD   standard deviation 
SWME   10-g Semmes-Weinstein monofilament examination 
ys   years 
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